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Cytokine Networks In Esophageal Squamous Cell Carcinoma
Abstract
Esophageal cancer is one of the top reasons for cancer-related deaths worldwide, and esophageal squamous
cell carcinoma (ESCC) accounts for up to 90% of all esophageal cancer cases. One of the major reasons for
the high mortality rate is the lack of targeted therapies for ESCC, particularly for advanced stage disease. The
tumor microenvironment (TME) is a complex system of multiple cell types (fibroblasts, immune cells, blood
and lymphatic vessels, etc.) that supports tumor growth in various ways. We aimed to investigate some of the
mechanisms of dynamic interaction between tumor cells and TME components and to identify approaches to
targeting these interactions therapeutically.
Desmoplasia, or deposition of connective tissue components (fibroblasts and extracellular matrix (ECM)), is
a pronounced histological feature of ESCC. Previous research from the Rustgi lab and others has underscored
the importance of cancer-associated fibroblasts (CAFs) and ECM components for ESCC progression. We
have identified two cytokines that mediate these effects: IL-6 and RANTES. Through in vitro studies we have
confirmed the relevance of these cytokines to human ESCC and determined that they function mostly
through activation of STAT3 and ERK1/2 signaling pathways. We have also validated IL-6 and RANTES as
novel targets for ESCC therapy by using tocilizumab (human IL-6R antibody) and maraviroc (CCR5
inhibitor) to inhibit the growth of subcutaneous ESCC xenotransplants in vivo.
Chronic inflammation and immunosuppressive microenvironment are also essential contributors to ESCC
pathogenesis. We have identified the ectoenzyme-receptor CD38 as a driver of expansion of myeloid-derived
suppressor cells in several murine models of ESCC. We have also identified six cytokines (IFNγ, TNFα,
CXCL16, IGFBP-3, IL-6 and RANTES) as promoters of CD38 expression by these cells in vitro. To
determine whether CD38 is a valuable target for therapy, we have utilized a neutralizing antibody to CD38 to
suppress tumor growth in a syngeneic murine model of ESCC.
In summary, we have identified novel mechanisms of interaction between tumor cells, CAFs and myeloid-
derived suppressor cells in esophageal TME. Furthermore, we have tested three independent in vivo
approaches to therapeutic targeting of these mechanisms that can potentially improve the clinical outcomes of
ESCC treatment.
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ABSTRACT 
CYTOKINE NETWORKS IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA 
Tatiana Karakasheva 
Anil K. Rustgi 
 Esophageal cancer is one of the top reasons for cancer-related deaths 
worldwide, and esophageal squamous cell carcinoma (ESCC) accounts for up to 90% of 
all esophageal cancer cases. One of the major reasons for the high mortality rate is the 
lack of targeted therapies for ESCC, particularly for advanced stage disease. The tumor 
microenvironment (TME) is a complex system of multiple cell types (fibroblasts, immune 
cells, blood and lymphatic vessels, etc.) that supports tumor growth in various ways. We 
aimed to investigate some of the mechanisms of dynamic interaction between tumor 
cells and TME components and to identify approaches to targeting these interactions 
therapeutically. 
 Desmoplasia, or deposition of connective tissue components (fibroblasts and 
extracellular matrix (ECM)), is a pronounced histological feature of ESCC. Previous 
research from the Rustgi lab and others has underscored the importance of cancer-
associated fibroblasts (CAFs) and ECM components for ESCC progression. We have 
identified two cytokines that mediate these effects: IL-6 and RANTES. Through in vitro 
studies we have confirmed the relevance of these cytokines to human ESCC and 
determined that they function mostly through activation of STAT3 and ERK1/2 signaling 
pathways. We have also validated IL-6 and RANTES as novel targets for ESCC therapy 
by using tocilizumab (human IL-6R antibody) and maraviroc (CCR5 inhibitor) to inhibit 
the growth of subcutaneous ESCC xenotransplants in vivo.  
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 Chronic inflammation and immunosuppressive microenvironment are also 
essential contributors to ESCC pathogenesis. We have identified the ectoenzyme-
receptor CD38 as a driver of expansion of myeloid-derived suppressor cells in several 
murine models of ESCC. We have also identified six cytokines (IFNγ, TNFα, CXCL16, 
IGFBP-3, IL-6 and RANTES) as promoters of CD38 expression by these cells in vitro. To 
determine whether CD38 is a valuable target for therapy, we have utilized a neutralizing 
antibody to CD38 to suppress tumor growth in a syngeneic murine model of ESCC. 
 In summary, we have identified novel mechanisms of interaction between tumor 
cells, CAFs and myeloid-derived suppressor cells in esophageal TME. Furthermore, we 
have tested three independent in vivo approaches to therapeutic targeting of these 
mechanisms that can potentially improve the clinical outcomes of ESCC treatment. 
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Esophageal squamous cell carcinoma 
Esophageal cancer is a major cause of cancer-related death worldwide: 455,800 
new cases were reported and 400,200 deaths occurred from this disease in 2012 (Torre 
et al., 2015). There are two major subtypes of esophageal cancer: esophageal 
squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC), and while 
the latter is more prevalent in North America and Europe, ESCC is the subtype that 
accounts for 90% of all esophageal cancers worldwide (Rustgi and El-Serag, 2014). 
According to the SEER database, 16,910 new cases (1% of all cancers)  and 15,690 
deaths (2.6% of all cancer-related deaths) are predicted to occur in the US in 2016 
(Howlader N, et al., 2016).  
Over the past three decades, there was a significant increase in overall median 
survival (from 6 months in 1970s to 10 months in 2000s) and 5-year survival rate (9% to 
22%). However, these improvements can be attributed almost exclusively to advances in 
early detection: increased survival was seen mostly in patients with localized disease 
and to a lesser extent in patients with regional disease (Njei et al., 2016). The use of 
surgery and neoadjuvant chemoradiation therapy have also increased, implying that 
targeted use of these treatment approaches also contributed to improved survival. 
Importantly, when ESCC and EAC data were analyzed separately, it became clear that 
the increased survival has been achieved for EAC only. Therefore, despite rising 
incidence, these patients have better long-term survival prognosis than patients with 
ESCC (Njei et al., 2016). These data clearly indicate a need for better understanding of 
the biology of, and novel therapeutic options for, ESCC.  
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Though both types of cancer arise in the same organ, ESCC and EAC are in fact 
distinctly different diseases. In addition to different histology and long-term survival 
statistics described above, they even arise in different parts of the esophagus: ESCC 
occurs in the lower and mid-esophagus, while EAC is most common in the distal part 
(Napier et al., 2014). The risk factors for the two subtypes are also distinct: alcohol and 
tobacco use, particularly in synergy, are most strongly associated with ESCC, while 
gastroesophageal reflux disease (GERD), obesity (particularly the visceral fat) and 
alcohol consumption (less strongly than for ESCC) are the major risk factors for EAC 
(Rustgi and El-Serag, 2014). Finally, genetic risk factors differ as well between the two 
disease: mutations in the TP53, RB1, CDKN2A, PIK3CA, NOTCH1, NFE2L2, ADAM29 
and FAM135B genes are most frequent in ESCC (Song et al., 2014), while TP53, 
CDKN2A, SMAD4, ARID1A, and PIK3CA mutations occur most often in EAC (Dulak et 
al., 2013). 
The tumor microenvironment 
 Historically, investigation of cancer biology initially focused on the tumor cell: its 
physiology, genetic (and later epigenetic) profiles, and signaling pathways. The first 
generations of cancer therapeutics were developed based on this research. Yet, despite 
all the breakthrough discoveries in those areas, clinical oncology still faces major 
obstacles – from the toxicity induced by early chemotherapeutic agents to development 
of chemo- and radioresistance, resistance to diverse targeted therapeutics, and tumor 
metastases, all of which stand in the way of developing effective cures for cancer. 
 The concept of tumor microenvironment (TME) first gained attention in the late 
XIX century, when Stephen Paget developed his “seed and soil” theory. Dr. Paget’s 
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observation that “when a plant goes to seed, its seeds are carried in all directions, but 
they can only live and grow if they fall on congenial soil” (Paget, 1889) prompted the 
medical community to take a closer look at the “soil” that allowed the tumor to establish 
and progress. Sadly, this hypothesis and the exciting research that it invited laid dormant 
for almost a century, possibly due to the fact that Dr. Paget’s views contradicted the then 
predominant opinion, according to which the cancer cell, once carried by blood or lymph 
to a distant organ, can remodel that site to suit its needs for successful metastasis.  
Only in the 1970s was the “seed and soil” hypothesis revisited, this time gaining 
the new appreciation (Witz, 2009). In his seminal editorial, Robert Auerbach wrote that 
“In a time where the primary emphasis in cancer research is at the level of gene 
expression, of regulation and of epigenetic modification of the "seed," those 
individuals…, who study the properties of the host environment should not be ignored. 
Not only are the observations of the 'soil' useful, they provide essential information 
without which we will not be able to understand the nature of the metastatic process” 
(Auerbach, 1988). Since then, a plethora of scientific reports have been published that 
have helped to shape our understanding of the nature of the TME into what it currently 
is: a complex system consisting of multiple cellular components (fibroblasts, multiple 
immune cell subpopulations, microvasculature represented by endotheliocytes and 
pericytes, adipocytes) and the extracellular matrix (ECM), which is a complex system of 
biopolymers (polysaccharides such as proteoglycans and hyaluronic acid, collagen and 
elastin fibers, fibronectins), matricellular proteins (non-structural proteins that can modify 
the ECM, such as osteopontin, periostin and SPARC) and various growth factors and 
cytokines (EGF, HGF, VEGF, TGFβ) embedded in this matrix. The “official status” of the 
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TME in the field of cancer research has been sealed, when its components have been 
incorporated into the famous concept of “hallmarks of cancer” to underscore that “Most 
of the hallmarks of cancer are enabled and sustained to varying degrees through 
contributions from repertoires of stromal cell types and distinctive subcell types” 
(Hanahan and Coussens, 2012). 
In the early 1990s it became increasingly clear that a deeper understanding of 
the TME’s dynamic nature and role in cancer progression was needed. For example, in 
his keynote address to the attendees of the Third International Conference on the 
Interaction of Radiation Therapy and Systemic Therapy in 1990, Ralph Durand stated 
that “that the cellular microenvironment can play a major role in modifying the activity of 
radiation and chemotherapy”, and he proceeded to suggest “some potential for new 
treatment strategies designed specifically to exploit the tumor microenvironment” 
(Durand, 1991). Later research proved Dr. Durand right: for example, increasing 
evidence exists of chronic inflammation promoting chemoresistance via activation of 
signaling pathways, most notably STAT3, in the tumor cells (Lee et al., 2014a; Spitzner 
et al., 2014; Wörmann et al., 2016), while the cancer-associated fibroblasts (CAFs) are 
also well known to promote resistance to therapy via multiple mechanisms, including 
secreted factors (Meads et al., 2009), exosomes (Hu et al., 2015) and modifying cancer 
cell metabolic pathways (Pavlides et al., 2009; Ying et al., 2012). Furthermore, CAFs 
can affect the delivery of therapeutics to the tumor by affecting angiogenesis (Goel et al., 
2012) or the biophysical characteristics of the ECM (Provenzano et al., 2012). 
One of the most fascinating features of the TME is its plasticity: unlike the cancer 
cells, which acquire a whole portfolio of mutations as they evolve, the TME components 
6 
 
generally do not acquire mutations (Lee et al., 2014b; Witz, 2008). This implies that it 
may be possible to educate the TME and de-differentiate its pro-tumorigenic 
components back into their normal, anti-tumorigenic state.  
The immune milieu in tumor microenvironment 
 The immune part of the TME comprises the cells belonging to the innate immune 
system (macrophages, neutrophils, dendritic cells, mast cells and myeloid derived 
suppressor cells), as well as effectors of the adaptive immunity (T and B lymphocytes). 
 Tumor associated macrophages (TAMs) are possibly the most common immune 
cell subtype in the TME. Macrophages represent the terminal differentiation state of a 
monocyte, which becomes adapted to residence within a certain organ. As is often the 
case with immune cells, macrophages are a very heterogeneous group of cells, and 
multiple classification schemes exist. The traditional approach is to subdivide the 
macrophages into M1 and M2 subtypes. M1, or classically activated, macrophages are 
generally induced by IFNγ and secrete high levels of pro-inflammatory cytokines (e.g. 
TNFα, IL-6, IL-1, IL-12). By contrast, M2, or alternatively activated, macrophages can be 
induced by IL-4, IL-10 or IL-13 secrete low levels of IL-12 and high levels of the anti-
inflammatory cytokine IL-10 (Grivennikov et al., 2010). However, both M2 and M1 
macrophages remain fairly plastic. Most of the TAMs are M2, and can be further sub-
categorized into angiogenic, immunosuppressive, invasive, metastasis-associated, 
perivascular, and activated macrophages (Komohara et al., 2016). TAMs have been 
linked to numerous pro-tumorigenic processes, such as maintenance of chronic 
inflammation in the TME, immunosuppression (direct or via activation of MDSCs), 
angiogenesis, tumor cell invasion and metastasis, while in general, the presence of 
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TAMs in the tumor correlates with poor prognosis (Grivennikov et al., 2010; Komohara et 
al., 2016). The classically activated M1 macrophages and dendritic cells, however, are 
essential for antigen presentation and CTL activation, which are the cornerstone of anti-
tumor immunity. 
 Historically, tumor-associated neutrophils (TANs) were considered to be a pro-
tumorigenic cell type (Fridlender and Albelda, 2012), and a number of studies 
demonstrated a correlation between the presence of TANs and poor prognosis in 
patients with melanoma, renal cancer, head and neck cancer and other cancer types 
(Swierczak et al., 2015). However, recent studies have shed some light on the temporal 
relationship between the tumor stage and the anti- or pro-tumorigenic capacity of 
neutrophils. For example, in early stage human lung cancer TANs are able to activate 
CTLs, but gradually loose this capacity at later stages (Eruslanov et al., 2014). 
 Myeloid-derived suppressor cells (MDSCs) originate from alternative 
differentiation of normal immature myeloid progenitors under the influence of tumor-
derived factors. These are a very heterogeneous group of myeloid cells that are united in 
their ability to suppress immune responses. MDSCs can be sub-divided further into the 
monocytic (M-MDSC) and perimorphonuclear (PMN-MDSCs, or granulocytic MDSCs) 
subsets based on their morphology and phenotype (Bronte et al., 2016). M- and PMN-
MDSCs employ different mechanisms for immunosuppression, and recent data suggest 
that each subset’s immunosuppressive capacity also varies based on the location. For 
example, PMN-MDSCs are the predominant subtype in peripheral lymphoid organs, 
where they promote the development of tumor antigen-specific T cell tolerance. At the 
same time, M-MDSCs tend to reside within the tumor and not only exert potent 
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immunosuppression (antigen-independent) function, but also rapidly differentiate into 
TAMs (Kumar et al., 2016). In general, the direct association between the presence of 
MDSCs and poor prognosis in cancer is well appreciated (Gabitass et al., 2011), and the 
specifics of MDSCs in esophageal cancer will be addressed in detail in Chapter 3 of this 
thesis. 
 T lymphocytes are also commonly found within the tumor, but unlike TAMs, 
different T cell subtypes bear either pro-or anti-tumorigenic properties. For example, high 
numbers of the CD8+ cytotoxic T lymphocytes (CTLs) or T helper 1 (Th1) cells can 
correlate with increased survival (Mao et al., 2016). At the same time, another T cell 
subset known as regulatory T cells (Treg) has widely appreciated pro-tumorigenic 
properties. Tregs are a subtype of CD4+ cells that express the transcription factor 
FoxP3, and their most investigated role in cancer is immunosuppression, which is 
mediated by the cytokines IL-10, IL-35 and TGF-β (Grivennikov et al., 2010). Multiple 
reports demonstrate a strong association between Treg infiltration and poor prognosis in 
cancer patients (Chen et al., 2016; Mao et al., 2016).  
 The infiltration of B lymphocytes into tumor tissue is in general associated with 
better prognosis, which can be mediated by more efficient antibody production or 
antigen presentation (interestingly, B cells can be recruited to the tumor in response to 
IFNγ production and tend to cluster with the CD8+ CTLs) (Guy et al., 2016; Mao et al., 
2016). Yet, similarly to T cells, a subset of B lymphocytes with immunoregulatory 
capacity (Breg) has also been identified in murine models of cancer. Bregs are activated 
by TGFβ and express the transcription factor FoxP3 (DiLillo et al., 2010). In human 
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cancer, these cells are also associated with PD-1 mediated immunosuppression (Guan 
et al., 2016). 
Cytokines and pro-inflammatory signaling in cancer 
 As soluble factors that exist to mediate interactions between cells, the role of 
various cytokines in cancer is well appreciated. In general, these factors act through 
activation of numerous downstream effector pathways, such as STAT1/3, NF-κB, Smad 
and apoptotic signaling. Most of the cell types present in the TME produce cytokines, 
which can be broadly categorized into anti-tumor (IL-12, IFNγ, TRAIL), pro-tumorigenic 
(IL-6, IL-23, IL-10, IL-17), and cytokines with direct roles on cancer cells (TGF-β, TNFα, 
IL-6, FasL). An overview of a few cytokines that have been most extensively studied in 
carcinogenesis will be provided below. 
 Transforming growth factor-beta (TGF-β), which normally plays an essential role 
in development of the tissues of epithelial and neural origin, is also a major tumor-
promoting cytokine. TGF-β is a most prominent regulator of angiogenesis, 
immunosuppression, epithelial-to mesenchymal transition (EMT), ECM remodeling, 
leading to tumor cell invasion and metastasis. The signaling events initiated by TGF-β 
include activation of the Smad2/3, p38, JNK, ERK and Akt/mTOR pathways, all of which 
contribute to tumorigenesis. Clinically, expression of TGF-β in the tumor correlates with 
poor differentiation, advanced stage, metastases and poor survival (Lin and Zhao, 
2015).  
 Interleukin-1 beta (IL-1β), a major regulator of the acute phase response, is 
secreted in response to activation of the inflammasome pathway. IL-1β signaling results 
in production of IL-1R, GM-CSF, G-CSF, TNFα, IL-6, IL-6, cortisol and nitric oxide, which 
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is accompanied by fever, muscle and joint pain, fatigue, hypotension, neutrophilia and 
thrombocytosis (Kasza, 2013). IL-1β plays a central role in cross talk between multiple 
sell types in the TME. For example, it promotes tumor cell invasion by activation of 
expression of several matrix metalloproteases (MMP-1,3,10 and 14). Furthermore, high 
levels of IL-1β in serum or tumor tissue correlates with advanced tumor stage in multiple 
tumor types (Whipple, 2015). 
 Interleukin 6 (IL-6), also known as “the truly pleiotropic cytokine” due to its 
numerous roles in the immune system, such as promoting activation and proliferation of 
T cells, differentiation of B cells, regulation of acute-phase response, as well as 
hormonal-like ability to regulate vasculogenesis, lipid metabolism, insulin resistance and 
neuropsychological processes (Hunter and Jones, 2015). The importance of IL-6 in 
tumor progression via regulation of such essential signaling pathways as STAT3, NF-κB 
and Wnt has been the subject of researchers’ interest for a while (Jarnicki et al., 2010), 
yet the detailed mechanisms beyond these events are not always understood. A 
substantial part of Chapters 2 and 3 of this thesis are dedicated to elucidating some of 
these mechanisms. 
 Chemokines as a class were originally defined as cytokines which regulate 
directional migration of immune cells. However, over time, it became clear that not only 
can chemokines direct migration of non-immune cells, but that their function is not 
limited to promoting chemotaxis. A good example is interleukin 8 (IL-8), also known as 
the CXC chemokine ligand 8 (CXCL8), or “the first chemokine” (Baggiolini et al., 1989). It 
is a classical chemoattractant for neutrophils, yet it can also activate downstream 
signaling pathways like p38-MAPK or Erk-MAPK, and due to this outcome IL-8 is 
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considered a pro-tumorigenic cytokine (Waugh and Wilson, 2008). Among other 
chemokines implicated in tumorigenesis are GROα/CXCL1, GROβ/CXCL2, 
GROγ/CXCL3, which affect cell proliferation and tumorigenicity in melanoma, ENA-
75/CXCL5, which regulates tumor growth, apoptosis and angiogenesis in melanoma, 
and macrophage pro-inflammatory chemokine-3α (MIP-3α/CCL20), which promotes 
tumor cell proliferation in pancreatic cancer (Coussens and Werb, 2002). 
RANTES/CCL5, another chemokine with pro-tumorigenic properties (Aldinucci and 
Colombatti, 2014), is a major focus of research described in Chapter 2 of this thesis. 
The tumor microenvironment of esophageal squamous cell carcinoma 
The pathogenesis of ESCC is tightly linked to chronic inflammation. In fact, 
serum levels of acute phase response mediators C-reactive protein (CRP) and IL-6 
correlate with the stage, depth of invasion and lymph node dissemination in ESCC 
(Groblewska et al., 2012). Furthermore, positive IL-6 staining of the tumor sections has 
been linked to distant metastases and poor treatment response in a study of 20 ESCC 
patients (Chen et al., 2013). In agreement with these findings, a novel inflammation-
based prognostic score (based on the CRP/Alb ratio) has been proposed to predict 
overall survival in a retrospective study of 423 ESCC patients (Wei et al., 2015).  
So far, only one study has attempted a more comprehensive analysis of the TME 
in tumors of  55 ESCC patients (Liu et al., 2012). In addition to overall high proliferative 
indices (based on Ki-67 staining), Dr. Liu and colleagues observed expansion of 
myofibroblasts (interestingly, the density of these cells correlated with dissemination to 
lymph nodes), increased microvessel density (quantified by CD34 staining), high levels 
of pro-angiogenic factors VEGF and IL-8, as well as  notable changes in the distribution 
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of immune cells throughout the tumors. The majority of T cells (CD3+) and macrophages 
(CD68+) were localized in the tumor stroma in the periphery and did not penetrate 
efficiently into the tumor epithelium. These findings imply the existence of an 
immunosuppressive milieu in these tumors. 
CAFs in ESCC 
One could argue that the cancer-associated fibroblasts represent the best-
studied TME compartment in ESCC (Fig. 1), at the level of both clinical prognostic 
associations and basic biology.  For example, Dr. Ha and colleagues have assessed the 
histopathological profile of CAFs in tissue samples from 116 ESCC patients and found 
that the expansion of CAFs correlated with poor prognosis, increased microvessel 
density and epithelial-to mesenchymal transition. Interestingly, expression patterns of 
the CAF markers used in this study were quite heterogeneous, and only αSMA, FSP1, 
and PDGFRα could serve as unfavorable prognostic factors for ESCC, while FAP and 
PDGFRβ offered no significance (Ha et al., 2014).  Another study of 97 patients 
investigated the association between expression of the most commonly used CAF 
marker (αSMA) and clinico-pathological features of ESCC: positive αSMA staining in the 
tumor stroma correlated with venous invasion, lymph node involvement, tumor 
recurrence and predicted poor survival in patients with stage I and II ESCC (Saito et al., 
2014). Finally, a study of 95 patients who had undergone esophagectomy for ESCC 
found that the abundance of CAFs in the original tumor correlated with a low 3-year 
overall survival rate (Cheng et al., 2015). 
A number of studies, including three publications from our lab, have identified 
mechanisms that contribute to the tumor-promoting properties of CAFs in ESCC. For 
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example, CAF-derived hepatocyte growth factor has been proved essential for invasive 
properties of ESCC cells in 3D culture via activation of the Met receptor (Grugan et al., 
2010) (Fig. 1B). Direct contact with collagen I fibers (deposited by fibroblasts) stimulates 
production of the lysosomal enzyme cathepsin B in tumor cells, which, in addition to 
directly modifying the ECM, also leads to enhanced secretion of TGFβ1 (Andl et al., 
2010) (Fig. 1A,B). Another mechanism by which CAFs promote invasion of ESCC cells 
into the ECM is by promoting expression of the matricellular protein periostin (in an 
EGFR- and mutant p53-dependent matter), which can only be detected in the invading 
tumor cells in vitro and in ESCC patient samples (Michaylira et al., 2010). The work 
described in Chapter 2 of this thesis is aimed to deepen our understanding of the ways 
in which the CAFs promote ESCC progression. 
Immune microenvironment in ESCC 
Since chronic inflammation plays such a major role in ESCC biology, many 
groups have focused their studies on the role of immune cells components in this 
disease. Existing evidence of the role of several such populations (MDSC, Treg, Th17 
and TAM) will be summarized in this section (Fig. 2).  
The myeloid-derived suppressor cells (MDSCs) are a heterogeneous population 
of immature myelocytes with one shared property: their ability to suppress activation of 
both innate and antigen-specific immune response. Chapter 3 of this thesis is dedicated 
to investigating the detailed mechanisms driving expansion of and acquisition of 
immunosuppressive capacity by MDSCs in a murine model of ESCC (Karakasheva et 
al., 2015). In addition to this work, another publication reports on the role of MDSCs in a 
chemical carcinogenesis-induced model of ESCC, and these data are accompanied by a 
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survey of an MDSC-like cell population in peripheral blood of ESCC patients, where the 
presence of these cells was associated with advanced disease, poor prognosis and 
resistance to therapy (Chen et al., 2014). 
 The involvement of tumor-associated macrophages (TAMs) has been well 
appreciated in many types of cancer, but in ESCC this cell subset has not been 
extensively studied. There are, however, some promising data: secretion of MCP-1 by 
ESCC cells results in TAM infiltration and production of pro-angiogenic factors, while the 
presence of TAMs is also associated with poor response to therapy and poor prognosis 
in ESCC (Shigeoka et al., 2013). Two subsets of T cells – Treg and Th17 – also 
contribute to formation of an immunosuppressive microenvironment in ESCC (Fig. 2). 
Tumor cell-derived chemokines CCL17 and CCL22 appear to be responsible for 
recruitment and expansion of Tregs in this disease. The presence of Tregs also has 
prognostic significance. Treg infiltration is associated with ESCC invasion, metastases, 
disease severity and survival post-chemotherapy. Furthermore, in patients receiving 
neoadjuvant chemoradiotherapy, retention of Tregs in the tumor is associated with poor 
treatment response and survival (Lin et al., 2016). Some reports demonstrate the 
relevance of the Th17 subset of T helper cells in ESCC: increased presence of these 
cells is detected in both peripheral blood and tumor tissue, and the degree of expansion 
correlates with disease stage (Lin et al., 2016). It is important to keep in mind, however, 
that the role of Th17 cells in cancer is still a subject to debate and more studies are 
needed to clarify this issue. 
15 
 
Pro-inflammatory signaling in ESCC  
 The signal transducer and activator of transcription 3 (STAT3) is among the 
most-investigated signaling pathways that regulate inflammation in cancer, and ESCC is 
not an exception: several studies, as well as our own work described in Chapter 2, have 
reported elevated levels activated STAT3, as well as its major inducer IL-6 and IL-6Rα 
(Leu et al., 2003; Yan et al., 2008). Furthermore, STAT3 activation correlates with poor 
prognosis in ESCC patients who have undergone esophagectomy for ESCC (Li et al., 
2014). Mechanistically, in vitro studies demonstrated that STAT3 signaling promotes 
production of anti-apoptotic factors (Leu et al., 2003), while small molecule inhibitor 
static restores radiosensitivity to ESCC cells in vivo (Zhang et al., 2014a). 
 The nuclear factor kappa B (NF-κB) pathway is another example of a cancer cell 
hijacking a normal immune signaling pathway to induce an aberrant state of chronic 
inflammation. Our lab has previously reported overexpression of the p65 subunit of NF-
κB in a genetic model of ESCC (Stairs et al., 2011). Overexpression of NF-κB have also 
been associated with poor prognosis in patients with ESCC (Hatata et al., 2012). IL-8, 
one of the major upstream regulators of NF-κB signaling, is also associated with disease 
progression, inflammation, metastases and poor prognosis in ESCC patients (Ogura et 
al., 2013). Interestingly, CCL5 (also known as RANTES), which is one of the main 
players in the mechanism described in Chapter 2, is a downstream target of the NF-κB 
pathway (Aldinucci and Colombatti, 2014). 
 It is important to note the existence of a complex interdependent cross-talk 
between the STAT3 and NF-κB signaling (Jarnicki et al., 2010).  One of the most 
prominent downstream targets shared by the two pathways is the gene encoding 
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cyclooxygenase-2 (COX-2). Interestingly, a positive correlation exists between COX-2 
expression and the degree of dysplasia in esophageal tissue (Zhi et al., 2006), while 
intense COX-2 staining is associated with poor prognosis and resistance to 
chemotherapy in patients with ESCC (Akutsu et al., 2011). Mechanistically, COX-2 
inhibition leads to decreased proliferation of and lower prostaglandin E2 production by 
ESCC cells in vitro, as well as to decreased tumor progression in vivo  (Zhi et al., 2006). 
 Finally, the programmed cell death protein-1 (PD-1) pathway, an increasingly 
popular target for cancer therapy, has also proven to be important in esophageal 
carcinogenesis (Fig. 2). Indeed, elevated expression of the pathway ligands PD-L1 and 
PD-L2 in cancer cells correlates with decreased survival in ESCC patients, while 
increased PD-L1 expression is associated with greater depth of tumor invasion and poor 
survival (Lin et al., 2016).  
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Figures and figure legends 
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Figure 1 
 
 
Figure 1-1: Stromal compartment of the esophageal TME. (a) Neoplastic cells 
secrete growth factors to activate quiescent fibroblasts designated as CAFs. CAFs can 
proliferate to contribute to desmoplasia, secreting ECM components such as fibronectin 
(FN) to enhance the development of the primary tumor niche. CAFs also secrete 
cytokines that promote tumor cell survival (anti-apoptosis). (b) Later in tumorigenesis, 
CAFs remodel the ECM with enzymes like lysyl oxidase (LOX) and MMPs as well as 
ECM components like dermatan sulfate (DS) and hyaluronan (HA) to promote invasion. 
CAFs also secrete growth factors that trigger tumor cells to undergo EMT and 
chemokines that induce tumor cell migration. CAFs can also promote angiogenesis via 
VEGF secretion. (Modified from Lin E., Karakasheva T., et al., Oncogene 2016). 
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Figure 2 
 
Figure 1-2: Immune landscape in esophageal cancer. Several immune cell types 
disrupt antitumor immunity (cytotoxic CD8+ T cells) in the TME. Tregs exert 
immunosuppressive function via direct contact with effector T cells or by molecules such 
as adenosine or immunosuppressive cytokines (IL-10 and IL-35). Th17 release 
adenosine by ectoenzymatic (CD39, CD73) function and have the ability to convert into 
Tregs (dashed line). MDSCs directly inhibit T-cell activation and NK cell cytotoxicity, 
while also inducing Tregs. TAMs and tumor cells both express PD-L1/2 to inhibit T-cell 
activation via the PD-1 receptor. Altogether, these cells suppress antitumor immunity 
while also promoting tumor growth and progression by various mechanisms. (Modified 
from Lin E., Karakasheva T., et al., Oncogene 2016). 
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Chapter 2 CHAPTER 2: The impact of interaction between tumor cells and cancer-
associated fibroblasts in esophageal squamous cell carcinoma 
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Abstract 
Esophageal cancer is a leading cause of cancer-related death worldwide. The 
prognosis for these patients remains poor, and targeted therapies are largely absent. 
Chronic inflammation and the reactive stroma are among the driving forces for 
esophageal cancer initiation, progression and dissemination. We have identified the 
cytokines IL-6 and RANTES as prominent mediators of this cross-talk in esophageal 
carcinogenesis. Loss of IL-6 or RANTES potently suppresses tumorigenesis in 3D 
models (organotypic and organoid) of esophageal cancer, as well as in subcutaneous 
xenograft transplant tumors. Furthermore, we found that inhibiting IL-6 or RANTES 
signaling (with tocilizumab, a neutralizing antibody to IL-6 receptor (IL-6R), or maraviroc, 
a small molecule CCR5 inhibitor, respectively), suppresses tumor growth in vivo via 
inhibition of STAT3 and ERK1/2 signaling pathways. We also demonstrate that co-
treatment with tocilizumab and maraviroc is more effective than either agent alone in 
vitro in 3D organotypic culture model of ESCC, providing a rationale for testing 
combination therapy in vivo. We propose inhibition of IL-6 and RANTES signaling as a 
novel approach to treatment of esophageal cancer, as well as potentially other types of 
cancer, particularly squamous cell carcinomas. 
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Introduction 
Esophageal cancer is the 8th most common cancer type and the 6th leading 
cause of cancer-related death worldwide (Napier et al., 2014). The 5-year survival rate 
for esophageal cancer patients is estimated to be 15-20%; furthermore, rather than 
declining, the incidence of esophageal cancer is expected to increase by 140% in the 
next 10 years (Napier et al., 2014). There are two subtypes of esophageal cancer – 
esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC), 
which are characterized by distinct histology, location and pathogenesis. ESCC 
represents up to 90% of all esophageal cases worldwide, but EAC is the prevalent type 
in the United States and Europe (Rustgi and El-Serag, 2014). The poor prognosis and 
increasing incidence and mortality indicate a need for improved understanding of 
mechanisms underlying esophageal cancer initiation and progression. Investigating the 
interaction between the tumor cells and surrounding microenvironment presents an 
opportunity to address some of these issues in a thoughtful and targeted way.  
Cancer-associated fibroblasts (CAFs) are among the most prominent cell types 
in the tumor microenvironment. CAFs have been reported to predict outcome (Ha et al., 
2014; Saito et al., 2014) and promote tumorigenesis (Zhang et al., 2009) in esophageal 
cancer. Previous reports from our lab have demonstrated that CAFs mediate ESCC cell 
invasion via secretion of hepatocellular growth factor (HGF) (Grugan et al., 2010) or 
cathepsin B (Andl et al., 2010). Furthermore, certain ECM components, secreted by 
CAFs, such as periostin, dermatan sulfate and fibronectin, are implicated in ESCC 
progression  (Michaylira et al., 2010; Thelin et al., 2012; Wong et al., 2013; Zhang et al., 
2005). It is therefore believed that therapeutically disrupting the cross-talk between 
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CAFs and tumor cells would be beneficial not only in esophageal cancer, but other types 
of cancer as well. 
Interleukin 6: a cytokine involved in the tumor microenvironment 
 Interleukin 6 (IL-6) is a pleiotropic cytokine, widely appreciated as a major 
regulator of the acute phase response, yet having numerous functions within the 
immune system, lipid metabolism, insulin resistance, mitochondrial function and the 
neuroendocrine system (Hunter and Jones, 2015). IL-6 signaling is mediated by a 
heterodimeric receptor complex comprised of the ligand-binding subunit (IL-6Rα, or 
CD126; (Yamasaki et al., 1988)) and the signal-transducing subunit (gp130, or CD130; 
(Hibi et al., 1990)). The best appreciated signaling event  induced by IL-6 is the signal 
transducer and activator of transcription 3 (STAT3) pathway, which has well 
characterized functions in promoting tumor progression (Guo et al., 2012). However, 
recent studies have demonstrated that IL-6 can activate additional signaling pathways, 
including MEK/ERK and PI3K/AKT (Costa-Pereira, 2014; Guo et al., 2012).  
 Increased secretion of IL-6 has been detected in multiple epithelial cancers, 
including, but not limited to, head and neck squamous cell carcinoma (HNSCC), lung 
cancer, colorectal cancer, gastric cancer, breast cancer,  ovarian carcinoma, and other 
cancers (Guo et al., 2012). In colorectal cancer patients, expression of IL-6 is associated 
with tumor stage, survival and metastasis, while colorectal cancer cell lines respond to 
IL-6 with stimulated growth in vitro (Waldner et al., 2012). In a chemical carcinogen-
induced model of gastric adenocarcinoma loss of IL-6 was associated with a dramatic 
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decrease in tumor incidence and reduced tumor number and size, as well as decreased 
levels of activated STAT3 (Kinoshita et al., 2013).  
In ESCC, IL-6 is known to suppress apoptosis (Leu et al., 2003) and cisplatin-
induced cytotoxicity (Suchi et al., 2011) in vitro. Furthermore, inhibition of STAT3 
promotes radiosensitivity in a subcutaneous xenograft ESCC model in vivo, while in 
ESCC patients positive IL-6 staining in the tumor is associated with poor prognosis 
(Chen et al., 2013). Serum levels of IL-6 in esophageal cancer patients correlate with 
tumor stage, depth of tumor invasion and dissemination to lymph nodes (Groblewska et 
al., 2012), while presence of soluble IL-6R in the serum is a predictor of poor response 
to neoadjuvant therapy in patients with ESCC (Makuuchi et al., 2013). In ESCC, IL-6 has 
been reported to activate STAT3, ERK1/2 and PI3K signaling in vitro, yet the latter 
pathway was not essential for the antiapoptotic activity of IL-6 (Leu et al., 2003). 
Reagents for therapeutic targeting of IL-6 signaling were initially developed for 
autoimmune diseases. Siltuximab, an IL-6 neutralizing antibody has been approved by 
the FDA for treatment of Castleman’s disease (Deisseroth et al., 2015), while 
tocilizumab, an antibody to IL-6Rα, has been approved by the FDA for treatment of 
rheumatoid arthritis (Thompson, 2010). Encouraged by favorable preclinical data 
(Goumas et al., 2015), a number of clinical studies was initiated to investigate the use of 
siltuximab in cancer, yet, while the therapy was generally well tolerated, no clinical 
efficacy was detected (Angevin et al., 2014; Rossi et al., 2015). These results have been 
attributed, in part, to the ability of tumor cells to increase IL-6 production, thus trapping 
the neutralizing antibody in circulation and preventing its access to the tumor (Hunter 
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and Jones, 2015). By contrast, neutralization of the IL-6 receptor has the potential to 
overcome this barrier. 
Treatment with tocilizumab resulted in suppressed tumor growth rate, 
accompanied by reduced STAT3 phosphorylation, in a murine model of oral cancer, the 
predominant subtype of HNSCC (Shinriki et al., 2009). Furthermore, tocilizumab has 
been proven to be effective in pre-clinical studies of breast cancer, where its 
administration resulted not only in stalled tumor growth, but also reduced lung 
metastases and depletion of CD11b+Gr-1+ myeloid-derived suppressor cells (Chang et 
al., 2013). A large number of clinical trials for the use of tocilizumab in cancer are 
ongoing (Table 1), and several novel agents are currently in pre-clinical development 
(Hunter and Jones, 2015). 
RANTES: a chemokine involved in the tumor microenvironment 
RANTES (regulated on activation, normal T-cell expressed and secreted), also 
known as CCL5, is a chemokine from the C-C chemokine ligand family. It is produced by 
activated T cells (but not B cells), platelets, monocytes, synovial fibroblasts and certain 
types of epithelia (Appay and Rowland-Jones, 2001). Production of RANTES is induced 
by NF-κB and JNK signaling (Chenoweth et al., 2012). Additionally, acetylated Snail, as 
well as AP-1 are viewed as transcriptional activators of RANTES, while CREB may be its 
transcriptional repressor (Hsu et al., 2014; Lv et al., 2013). In addition, adipocytes in the 
microenvironment and cellular ER stress may stimulate secretion of RANTES 
(D’Esposito et al., 2016; Zhang et al., 2014b) .  
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RANTES is a potent chemoattractant for eosinophils, monocytes, T cells and 
basophils (Kameyoshi et al., 1992; Kuna et al., 1992). However, it has other functions, 
such as promotion of proliferation, invasion and angiogenesis (Aldinucci and Colombatti, 
2014). RANTES acts through a number of G-protein-coupled receptors (GPCRs): CCR1 
(Neote et al., 1993), CCR3 (Ben-Baruch et al., 1995), CCR5 (Raport et al., 1996) and 
auxiliary receptors CCR4 (Udi et al., 2013) and CD44 (Roscic-Mrkic et al., 2003). 
Interestingly, these receptors can be activated by other chemokines, such as MIP-1α 
(CCR1), eotaxin (CCR3) and MIP-1β (CCR5). Among these GPCRs, CCR5 is by far the 
best-studied, due to its function as a co-entry receptor for the human immunodeficiency 
virus (HIV) (Deng et al., 1997). 
RANTES expression has been associated with several types of cancers. For 
example, its levels are elevated in both plasma and tumor tissue of patients with breast 
and cervical cancers (Niwa et al., 2001). Furthermore, patients with gastric 
adenocarcinoma have significantly higher levels of RANTES in serum, which are 
associated with reduced histological differentiation, greater degree of tumor invasion, 
advanced tumor stage and reduced overall survival (Sima et al., 2014). 
Certain functions of RANTES in cancer are related to its activity in the 
immunosuppressive cell populations.  For example, it contributes to recruitment, 
alternative differentiation and immunosuppressive capacity of myeloid-derived 
suppressor cells in a murine model of triple-negative breast cancer, as well as in an ex 
vivo differentiation assay of human patient-derived CD33+ suppressor cells (Zhang et al., 
2013). The binding of RANTES to CCR5 leads to phosphorylation of the p38 MAP 
kinase, while activation of JAK2/3 and subsequent phosphorylation of STAT1/3 (Wong et 
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al., 2001). Furthermore, RANTES-CCR5 signaling drives homing of regulatory T cells to 
the tumor and enhances their suppressive capacity in murine models of pancreatic and 
colorectal cancers (Chang et al., 2012; Tan et al., 2009). 
RANTES is essential in mediating the cross-talk between tumor cells and 
surrounding stromal cells. Treatment of human ovarian cancer cells with cisplatin 
induces secretion of RANTES by CAFs, which activates the STAT3 and PI3K/AKT 
signaling pathways in tumor cells, thereby leading to resistance to cisplatin (Zhou et al., 
2016). Furthermore, RANTES (along with IL-6) promotes mesenchymal stem cell-
induced migration of human breast cancer cells in vitro (Gallo et al., 2012). 
Tumor cell-autonomous functions of RANTES have been reported. RANTES-
CCR5-induced STAT3 signaling promotes tamoxifen resistance in human breast cancer 
cells in vitro (Yi et al., 2013). In human lung cancer cells, CCR5 ligation by RANTES 
promotes migration via activation of the PI3K/AKT and NF-κB signaling pathways 
(Huang et al., 2009). 
Historically, investigation of the pro-tumorigenic functions of RANTES has been 
focused on its ability to activate CCR5, yet, it is becoming apparent that other GPCRs 
are quite important as well. Importantly, pharmacological inhibition of CCR5 with TAK-
779, while able to suppress the growth of primary tumors, failed to prevent peritoneal 
dissemination of colorectal cancer cells in vivo, compared to treatment with a RANTES-
neutralizing antibody (Cambien et al., 2011). Accordingly, RANTES-CCR1 interaction 
has been reported to promote invasion of taxane-resistant prostate cancer cells via 
ERK1/2 and Rac signaling (Kato et al., 2013), while NF-κB signaling induced by 
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autocrine activation of CCR1 and CCR3 by RANTES drives metastatic dissemination of 
ovarian cancer cells (Long et al., 2012). 
There have been a number of studies to evaluate inhibition of RANTES as an 
approach to cancer therapy. Several small molecule inhibitors have been developed to 
target CCR5: maraviroc (Wood and Armour, 2005), vicriviroc (Strizki et al., 2005), TAK-
779 (Baba et al., 1999) and anibamine (Zhang et al., 2012). Maraviroc has been 
approved by the FDA and successfully used for HIV therapy (Van Der Ryst, 2015), 
resulting in its potential application to target RANTES in cancer. For example, treatment 
with maraviroc prevents development of tumors in a murine model of hepatocellular 
carcinoma (Ochoa-Callejero et al., 2013), inhibits growth of orthotopically transplanted 
colon cancer cells (Tanabe et al., 2016), reduces the capacity of gastric cancer cells to 
disseminate (Mencarelli et al., 2013) and prevents metastasis of basal breast cancer 
cells in vivo (Velasco-Velázquez et al., 2012). Finally, a pilot clinical study has been 
published where maraviroc was used in 11 patients with advanced refractory colorectal 
cancer. This resulted in central tumor necrosis and a partial remission of lung 
metastases. A subgroup of patients received maraviroc in combination with 
chemotherapy, leading to a partial response in 3/5 (60%) cases (Halama et al., 2016).  
Other GPCRs may significantly contribute to the pro-tumorigenic effects of 
RANTES (Cambien et al., 2011). Therefore, the capture of the ligand with a neutralizing 
antibody or a combination of multiple small molecule inhibitors may be beneficial. A 
selective CCR1 inhibitor J113863 (Pevida et al., 2014) and its trans-isomer UCB35625 
(Sabroe et al., 2000) have been developed and tested in vivo, but no reports of their 
utility as clinical therapeutic agents are available thus far. In addition to maraviroc, 
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mogamulizumab, a neutralizing antibody to human CCR4, is being actively studied in the 
clinic as a novel agent for therapy of hematologic malignancies (Table 1) since CCR4 is 
one of the receptors utilized by RANTES, mogamulizumab could be tested in solid 
malignancies as well. 
Of importance to our study, there is evidence for cooperation between IL-6 and 
RANTES in several contexts, including cancer. For instance, RANTES/CCR5 signaling 
promotes IL-6 secretion by human synovial fibroblasts via the PKCδ/c-Src/c-Jun and AP-
1 signaling pathways in a model of osteoarthritis (Tang et al., 2010). In combination with 
IL-6, RANTES can stimulate proliferation of prostate cancer cells in vitro via ERK1/2 
signaling (Colombatti et al., 2009). Furthermore, potent tumor-promoting signaling 
circuits converging on RANTES and IL-6 in murine models of KRAS-driven lung cancer 
(Zhu et al., 2014) and IKBKE-driven triple-negative breast cancer (Barbie et al., 2014) 
have been reported. Interestingly, there may be ways to therapeutically suppress the 
production of pro-tumorigenic cytokines: zoledronic acid can impair the secretion of 
RANTES and IL-6 in mesenchymal stem cells, thus blocking their interaction with breast 
cancer cells (Gallo et al., 2012). 
 In this study, we use 3D culture approaches and murine xenotransplant models 
to demonstrate a role for tumor cell-derived IL-6 and RANTES in mediating the 
interaction between tumor cells and CAFs in esophageal squamous cell carcinoma. We 
define STAT3 and ERK1/2 signaling pathways as the likely predominant downstream 
mediators of the two cytokines in ESCC. Furthermore, we confirm that IL-6 and RANTES 
are novel and promising targets for ESCC therapy that can be targeted by tocilizumab (a 
neutralizing antibody to human IL-6Rα), maraviroc (small molecule CCR5 antagonist), or 
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a combination of both. Given the existing evidence of involvement of IL-6 and RANTES 
in breast, lungs and gastric cancer progression, we propose that this treatment strategy 
can be expanded to other cancer types.   
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Results 
Interaction between tumor cells and CAFs induces changes in cell biology 
 Desmoplasia is one of the key characteristics of ESCC (Lin et al., 2016), which 
prompted us to investigate the consequences of interaction between the tumor cells and 
CAFs. First, we have evaluated the changes in gene expression profiles in TE11 cells 
grown in mono-culture, compared to co-culture with the FEF3303 esophageal 
fibroblasts. Upon magnetic bead-based purification from co-culture, RNA was extracted 
from the tumor cells, followed by qPCR analysis. We have found significant changes in 
expression of multiple genes encoding matricellular proteins (FBN1, POSTN, SPARC, 
THBS1), growth factors and their receptors (EGF, HGF, VEGFA, VEGFB, VEGFC, MET, 
PTK2, FLT1, KDR), EMT-related genes (CDH2, SNAIL2), cytokines, chemokines and 
their receptors (IL-6, CXCL1, CXCL5, IL-6R, CCR1, CCR4), as well as components of 
inflammatory signaling pathways (STAT3, SOCS3, SOCS2) (Fig. 1A).  
 We next decided to investigate the effect of co-culture on cell proliferation. 
Measured by flow cytometry (dilution of the CFDA-SE dye), three out of four ESCC cells 
lines (TE1, TE6, HCE7) had increased proliferation rates when co-cultured with 
fibroblasts (Fig. 1B). Furthermore, proliferation of either FEF3 or FEF3303 esophageal 
fibroblasts was significantly enhanced by any of the ESCC cells tested (Fig. 1B). 
 In a 3D organotypic culture model system, addition of FEF3303 esophageal 
fibroblasts to the epithelial layer (TE11) resulted in a dramatic increase in epithelial layer 
thickness, as well as enhanced invasion into the extracellular matrix (Fig. 1C, 1D). 
Importantly, co-injection of TE11 cells with FEF3303 or ESCC-Fb-1 fibroblasts 
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subcutaneously into flanks of nude mice significantly promoted tumor growth rate, when 
compared to TE11 cells alone (Fig. 1E). These findings underscore the importance of 
activated fibroblasts in ESCC initiation and progression. 
IL-6 and RANTES are potential mediators of cross-talk between tumor cells and 
CAFs in ESCC 
 To identify potential mediators of cross-talk between epithelial tumor cells and 
CAFs in esophageal cancer, we have conducted a cytokine array analysis of conditioned 
media from co-cultures of ESCC cells with esophageal CAFs. We have identified six 
cytokines (IL-6, RANTES, ENA-78, GRO-α, IL-8 and MCP3) with enhanced secretion in 
co-culture, compared to either cell line in mono-culture (Fig. 2A). Secretion of IL-6 was 
the most dramatically and specifically increased in co-culture, while RANTES was the 
second most-upregulated in co-culture. We have confirmed the cytokine array results for 
IL-6 and RANTES by ELISA and observed pronounced upregulation of both cytokines in 
co-culture of TE11 ESCC cells and FEF3303 fibroblasts (Fig. 2B).  
 We have immuno-stained sections of paraffin-embedded samples of human 
ESCC or normal esophagus for IL-6 and RANTES. Interestingly, we have observed 
increased staining for IL-6 and RANTES in both fibroblasts and epithelial cells in ESCC 
(Fig. 3A, B). Specifically, in the normal esophagus IL-6 is expressed at low levels in the 
fibroblasts, as well as the smooth musculature (muscularis mucosae), and is absent in 
the epithelial layer. By contrast, in ESCC high expression of IL-6 is found in fibroblasts 
and epithelial cells. RANTES is expressed at low levels in the normal esophageal 
epithelium and absent in normal stroma, while in ESCC RANTES expression in the 
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epithelium is intense, and a certain amount is detected in the fibroblasts. These data 
suggest that IL-6 and RANTES may be relevant to ESCC pathogenesis. 
Tumor cell-derived IL-6 promotes tumorigenic properties of ESCC  
 To investigate the role of epithelial cell-derived IL-6 in esophageal cancer, we 
have used the CRISPR/Cas9 method to knock out IL-6 in TE11 cells, TE11 IL-6KO1 and 
IL-6KO2 (Fig. 4). We have observed significant differences in two types of 3D culture 
and in vivo. The 3D organotypic cultures formed by TE11 IL-6KO cells reveal decreased 
epithelial layer thickness and reduced invasion (Fig. 5A). Furthermore, we found that 
TE11 IL-6KO cells formed smaller 3D organoids with “normalized” morphology, 
compared to IL-6WT cells (Fig. 5B). Subcutaneous xenograft tumors formed by the 
TE11 IL-6KO cells are characterized by stalled growth rates (Fig. 5C). 
Targeting IL-6 signaling as a therapeutic approach in ESCC 
 Since we found that IL-6 signaling drives ESCC progression, we conducted a 
therapeutic study using tocilizumab, a neutralizing antibody against the human IL-6Rα. 
Nude mice bearing subcutaneous xenograft tumors formed by TE11 and FEF3303 cells 
were treated with tocilizumab or a human IgG isotype control. Interestingly, tocilizumab 
treatment resulted in stalled tumor growth (Fig. 6A), which was accompanied by 
reduced STAT3 and ERK1/2 signaling (Fig. 6B). 
Tumor cell-derived RANTES promotes tumorigenic properties of ESCC  
 We have next generated single cell-derived subclones of TE11 cells with 
CRISPR/Cas9-mediated knockout of RANTES: TE11 RantesKO1 and RantesKO2 (Fig. 
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4). In the 3D organotypic cultures formed by TE11 RantesKO cells there were fewer 
nucleated epithelial layers with reduced invasion (Fig. 7A). In addition, we found that 
RANTES-deficient 3D organoids were smaller and had “normalized” morphology (Fig. 
7B). Finally, subcutaneous xenograft tumors formed by the TE11 RantesKO cells had 
decreased growth rates, compared to RantesWT tumors (Fig. 7C). 
Targeting RANTES signaling as a therapeutic approach in ESCC 
To target RANTES signaling in vivo, we selected maraviroc, a small-molecule 
antagonist of CCR5. We found that treatment with maraviroc suppressed growth of 
subcutaneous xenograft tumors formed by TE11 and FEF3303 cell lines co-implanted 
into hind flanks of nude mice (Fig. 8A), compared to treatment with the vehicle (DMSO). 
Surprisingly, tumors from the maraviroc-treated animals had significantly reduced 
ERK1/2 signaling in both epithelial cells and fibroblasts, which was accompanied by a 
trend of reduced STAT3 signaling (Fig. 8B). 
 
Co-targeting of IL-6 and RANTES is a preferential strategy to ESCC therapy in 
vitro 
 Our results indicate that IL-6 and RANTES play an important role in ESCC 
pathogenesis and that at least part of their functions are mediated through the STAT3 
and ERK1/2 signaling pathways (Fig. 6,8). This led us to investigate whether 
simultaneous inhibition of IL-6 and RANTES signaling may provide a further therapeutic 
benefit. To that end, we treated 3D organotypic ESCC cultures with tocilizumab, 
maraviroc or a combination of both. Interestingly, we have found that though either drug 
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alone or in combination suppressed tumor cell invasion, only the combination of 
tocilizumab and maraviroc produced a significant reduction in the number of nucleated 
epithelial layers (Fig. 9). These data indicate that simultaneous inhibition of both IL-6 
and RANTES-induced signaling may indeed be a better approach for the treatment 
ESCC, although in vivo testing of this hypothesis is needed. 
STAT3 and ERK1/2 signaling promotes ESCC tumorigenesis 
 We have next treated 3D organotypic cultures of ESCC with small molecule 
inhibitors of STAT3 and MEK/ERK signaling pathways (stattic and trametinib, 
respectively). Surprisingly, while treatment with either drug individually suppressed 
tumor cell invasion, the combination of stattic and trametinib inhibited invasion even 
more efficiently than either drug alone (Fig. 10A,B). Only STAT3 inhibition led to 
reduced number of nucleated cells in the epithelial layer, while only MEK/ERK inhibition 
efficiently suppressed cell proliferation, measured by Ki-67 staining (Fig. 10A,B). 
Interestingly, only combination of stattic and trametinib promoted apoptosis, while mono-
therapy with either drug induced no change, measured by immune-staining for cleaved 
caspase 3 (Fig.10A,B). These data suggest that the signaling pathways induced by IL-6 
and RANTES promote tumor cell invasion, proliferation and evasion of apoptosis in 
ESCC. 
IL-6 signaling as a therapeutic target in multiple types of cancer 
To determine the potential of targeting IL-6 signaling in other cancers besides 
esophageal, we performed in silico survival analysis using IL-6 and IL-6R expression 
(RNAseq) data acquired from TCGA. Remarkably, we found that low relative expression 
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of IL-6 and IL-6R was correlated with improved survival, not only in esophageal cancer 
but in the TCGA pan-cancer dataset (Fig. 11A). In addition, immunohistochemical 
staining for IL-6 in head and neck squamous cell carcinoma (HNSCC) and gastric 
adenocarcinoma showed overexpression in tumor sections compared to matched 
normal oral and gastric mucosa, respectively (Fig. 11B,C). (All data in this section are 
used with permission from Eric Lin). 
  
37 
 
Discussion 
The importance of the tumor microenvironment in cancer in general, and in 
esophageal cancer specifically, is well appreciated (Lin et al., 2016). Yet, the precise 
mechanisms of interaction between different components of the TME and the tumor cells 
remain to be elucidated. We focused our attention on fibroblasts, because of existing 
evidence linking CAFs to prognosis and therapeutic outcome in ESCC (Ha et al., 2014; 
Saito et al., 2014). Specifically, we wanted to identify novel mediators of interaction 
between CAFs and esophageal tumor cells.  
 Based on the cytokine array results, IL-6 and RANTES were selected as likely 
candidates, since they were specifically upregulated in co-cultures of ESCC and 
esophageal CAFs, compared to mono-cultures (Fig. 2). This was strengthened by the 
IHC staining of human ESCC biopsies, where either IL-6 or RANTES staining was 
significantly stronger in both epithelial cells and fibroblasts, compared to normal 
samples. Previous studies have demonstrated the role of ESCC cell-derived IL-6 in 
evasion of apoptosis (Leu et al., 2003), and our findings support this premise. 
Importantly, we show herein that expression of IL-6 by tumor cells is induced through 
interaction with CAFs. Yet, our data from 3D organoid cultures suggest an autocrine IL-6 
signaling mechanism (Fig. 5B), in addition to paracrine signaling induced by fibroblast-
derived IL-6. To our knowledge, no reports describing the function of RANTES in ESCC 
have been published. Our observations regarding the role of RANTES in the growth and 
invasiveness of 3D tumor cultures (Fig. 7), are noteworthy and in agreement with current 
perspectives on the importance of RANTES in other cancers (Aldinucci and Colombatti, 
2014).  
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Tocilizumab is widely used in clinic to inhibit IL-6 signaling in autoimmune 
diseases, and a number of pre-clinical studies have indicated its efficacy in cancer. 
Since our data demonstrate that IL-6 promotes esophageal carcinogenesis, we have 
tested tocilizumab in a xenograft model of ESCC and observed a potent tumor-
suppressive effect, which was accompanied by decreased STAT3 and ERK1/2 signaling 
in both epithelial and fibroblast compartments (Fig. 6). Furthermore, we provide 
evidence of IL-6 involvement in pathogenesis of multiple types of cancer, such as head 
and neck squamous cell carcinoma and gastric adenocarcinoma (Fig. 11). Similarly, 
prompted by our finding that RANTES is also important for ESCC progression, we 
sought to pharmacologically inhibit its signaling (at least partially) in vivo. In our 
xenograft model, maraviroc suppressed ESCC tumor growth, likely via inhibition of 
STAT3 and ERK1/2 signaling pathways (Fig. 8).  
Importantly, we demonstrate that co-inhibition of signaling induced by IL-6 and 
RANTES provides a better tumor-suppressive effect than inhibition of either cytokine 
alone in vitro (Fig. 9). Interestingly, a synergistic interaction between IL-6 and RANTES 
has been previously described in aggressive subtypes of lung and breast cancer (Barbie 
et al., 2014; Zhu et al., 2014). Along with our data, this suggests that co-targeting IL-6 
and RANTES could provide for a superior treatment strategy not only in ESCC, but in 
other types of cancer. 
 In agreement with previous publications (Aldinucci and Colombatti, 2014; Leu et 
al., 2003), we find that the pro-tumorigenic role of IL-6 and RANTES in ESCC is 
mediated via STAT3 and ERK1/2 signaling pathways. In addition to suppression of 
apoptosis, we also found that these pathways mediate tumor cell proliferation and 
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invasion (Fig. 10). These findings provide a rationale for potential future studies of 
combining downstream inhibitors of these pathways for therapeutic application, which 
could provide a better outcome, compared to “upstream intervention”, such as receptor 
blockade with tocilizumab and/or maraviroc. 
 Since the key role of activated stroma in the establishment and progression of 
cancer in general, and ESCC in particular, is no longer under question, the next logical 
step should be to use this knowledge in designing the new generation of cancer 
therapeutics. In addition to promoting tumorigenesis, CAFs are known to contribute to 
resistance to multiple treatments, including neoadjuvant chemotherapy, anti-angiogenic 
therapy, and receptor tyrosine kinase inhibitors (Pietras and Östman, 2010). We have 
identified two cytokines that mediate the interaction between tumor cells and CAFs in the 
esophageal cancer microenvironment, as well as the key signaling pathways utilized by 
these cytokines. These data shall be used to develop novel targeted approaches to 
cancer therapy, as well as to improve the currently used strategies. For example, 
combining inhibition of IL-6 and RANTES with chemo- or radiotherapy may produce 
superior results. 
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Materials and methods 
Cell lines and reagents 
The TE and HCE cell lines were cultured in DMEM supplemented with 
10% FBS (Sigma) and 1x penicillin/streptomycin (Invitrogen) in 5% CO2 as 
described previously (Okano et al., 2000). FEF3 and FEF3303 cell lines were 
cultured in DMEM supplemented with 15% FBS (HyClone) and 1x 
penicillin/streptomycin in 5% CO2 as described previously (Okawa et al., 2007). 
The ESCC-Fb-1 and ESCC-CAF-J1 cell lines have been generated from 
esophageal biopsies. The tissues were incubated in dispase/collagenase/Y27632 
solution for 45 min at 37oC (vortexed every 10 minutes and mechanically 
disrupted with a P1000 pipette tip). Preparations were incubated for 10 minutes 
at 37oC in 0.25% trypsin/EDTA. Soybean trypsin inhibitor (Sigma) was used to 
inactivate trypsin. The resulting cell suspension and tissue fragments were forced 
through a 70 μm strainer, centrifuged, resuspended in fibroblast media 
supplemented with fungizone (Gibco) and gentamicin (Gibco) and seeded into 
one well of a 6-well plate. Culture media was replaced every 48 hours or as 
needed.  
 Stattic, trametinib and Maraviroc were purchased from Selleckchem, and 
tocilizumab - from the pharmacy of the Hospital of the University of Pennsylvania. 
Human IgG control was from Sigma. 
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3D organoid and organotypic culture 
 The cells were trypsinized, mixed with matrigel (BD) and seeded at 3000 
cells/well. After matrices solidified, growth media were added (CnT Prime 3D 
Barrier Media for Epidermal Models, ZenBio) and replaced every 48-72 hours. 
For IHC, organoids were recovered on day 12 from matrigel with dispase 
digestion, fixed overnight in 4% paraformaldehyde and embedded in 2% Bacto-
Agar:2.5% gelatin before dehydration and embedding in paraffin.  
 TE11 cells were grown in organotypic culture as described previously 
(Kalabis et al., 2012), with the following modifications. Transwell inserts (30mm, 
PET, 0.4μm pore; Millipore) were used to support the 3D collagen/matrigel 
matrices, containing 27% Nutragen bovine collagen solution type I (Advanced 
Biomatricx), 18% matrigel (BD), 1× minimal essential medium with Earle’s salts 
(BioWhittaker), 1.68 mM L-glutamine (Cell- gro), 10% fetal bovine serum 
(Hyclone), 0.15% sodium bicarbonate (BioWhittaker), and 2×104 FEF3303 
fibroblasts. On day 7 of culture, 2.5x105 epithelial cells were seeded on top of the 
matrices. On day 15, the cultures were fixed in Zn-buffered formalin (Thermo) for 
2 hours at 4oC before dehydration and embedding in paraffin. 
Real-time qPCR 
RNA was isolated using the RNAqueous-4PCR kit (Ambion).  cDNA was 
generated using oligo-dT primers and Superscript II Reverse Transcriptase (Life 
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Technologies).  Real-time PCR was performed using validated SYBR Green 
primers and ABI7000 and ABI StepOne instruments (Applied Biosystems).   
FACS 
Cells were labeled with CFDA-SE (Invitrogen; 1 or 0.1 μM for epithelial 
cells or fibroblasts, respectively) for 30 minutes at 37oC, quenched for 30 minutes 
at 37oC, trypsinized and seeded into co- or mono-cultures. After 72 hours, the 
cells were trypsinized, resuspended in PBS with 1% BSA and 0.01% sodium 
azide. Samples were analyzed on a FACScalibur (BD) or Accuri (BD). Data were 
analyzed using FlowJo (Treestar). 
Cytokine array 
3x105 cells were seeded per 6 cm dish and grown in 5 mL DMEM with 
10% FBS (HyClone) and 1x penicillin/streptomycin. Each culture condition was 
carried out in duplicate. After 72 hours, conditioned media were collected, frozen 
and stored at -80oC. The relative concentration of 42 cytokines was measured 
using the Human cytokine array G3 (Raybiotech). 
ELISA 
Cytokine levels in culture supernatants were quantified using the Human 
IL-6 ELISA MAX and Human CCL5 (RANTES) ELISA MAX kits (BioLegend) 
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according to the manufacturer’s instructions. Absorbance was measured on the 
Sunrise Microplate Reader (TECAN). 
Histology 
 ESCC tissue samples were obtained as surgical biopsies from Kagoshima 
University Hospital, as described previously (Natsuizaka et al., 2014). The clinical 
materials were obtained from informed-consent patients according to the 
Institutional Review Board standards and guidelines. IHC and 
immunofluorescence were performed as described previously (Karakasheva et 
al., 2015).  
Xenograft tumor growth studies 
 All animal studies were approved by the Institutional Animal Care and Use 
Committee (IACUC) at the University of Pennsylvania. A total of 6x106 cells (all 
epithelial, or 5x106 epithelial cells with 106 fibroblasts) resuspended in 50 μl 
matrigel were injected subcutaneously into rear flanks of female athymic nude 
mice (6-10 weeks old, Taconic). Tumors were measured twice a week after 
becoming palpable. For therapeutic studies, tocilizumab or human IgG control 
were delivered intraperitoneally at 10mg/kg three times a week; maraviroc or 
vehicle control (DMSO) were delivered intraperitoneally at 10mg/kg daily.  
 
44 
 
 
Statistical analysis 
 Student’s t-test was used to determine significance. ANOVA analysis was 
used to determine significance for multi-parameter comparisons. Unless noted 
otherwise, the p-values are listed on graphs. All analyses were performed in R 
version 3.2.2 (R Foundation for Statistical Computing, Vienna, Austria). 
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Figures and figure legends 
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Figure 2-1: Direct interaction between tumor cells and CAFs induces changes in 
cell biology. (A) qPCR analysis of gene expression in ESCC cells (TE11) co-cultured 
with CAFs (FEF3303), compared to mono-culture (n=2/group; *p<0.05). (B) Relative 
proliferation rates of ESCC cells (TE1, TE6, TE11, HCE7) and CAFs (FEF3, FEF3303) 
in mono- or co-culture, measured by CFDA-SE fluorescence dilution (n=3/group; *p=10-
4, 10-6, 10-5, 10-6, 0.007; **p<10-3; ***p<10-2). (C) Representative images of 3D 
organotypic cultures where epithelial cells have been seeded alone (TE11) or mixed 
directly with CAFs (TE11+FEF3303) (n=3/group). Number of nucleated epithelial layers 
and relative invasive area are quantified. (D) Growth kinetics of subcutaneous xenograft 
tumors formed by ESCC cells alone or co-injected with CAFs (n=4/cohort; *p<0.05). P-
values calculated via Student’s t-test, p≤0.05 considered statistically significant. 
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Figure 2 
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Figure 2-2: IL-6 and RANTES are potential mediators of cross-talk between tumor 
cells and CAFs in ESCC. (A) Representative results of the cytokine array conducted on 
conditioned media from mono- and co-cultures of ESCC cells (TE1, TE6, TE11, HCE7) 
and CAFs (FEF3, FEF3303) (n=2/group). (B) Concentration of IL-6 and RANTES in 
conditioned media from mono- and co-culture of ESCC cells and CAFs, measured by 
ELISA (n=3/group). P-values calculated via Student’s t-test, p≤0.05 considered 
statistically significant. 
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Figure 3 
 
 
Figure 2-3: IL-6 and RANTES are overexpressed in epithelial and stromal 
compartments of ESCC. (A, B) Representative images of normal esophagus and 
ESCC stained immunohistochemically for IL-6 or RANTES (n=40). Histopathological 
scoring results are shown on the right. P-values calculated via Student’s t-test, p≤0.05 
considered statistically significant. 
  
51 
 
Figure 4 
 
Figure 2-4: Quality-control of the IL-6 and RANTES-knockout subclones of TE11 
ESCC cell line. Levels of corresponding cytokines in cell culture conditioned media 
were measured by ELISA and compared to wild-type TE11 conditioned medium, as well 
as to DMEM (negative control). Results shown are for the subclones at passage 3 post-
transfection with the CRISPR/Cas9 construct. The stability of knockout was confirmed by 
ELISA for up to passage 12 post-transfection (n=3 wells/clone). P-values calculated via 
Student’s t-test, p≤0.05 considered statistically significant. 
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Figure 5 
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Figure 2-5: Tumor cell-derived IL-6 promotes tumorigenic properties in ESCC. (A) 
Representative images of 3D organotypic cultures (Hematoxylin-Eosin stained paraffin-
embedded sections) formed by wild-type or IL-6 knockout TE11 cells (n=2/clone). (B) 
Representative images of 3D ESCC organoids (brightfield and Hematoxylin-Eosin 
staining of paraffin-embedded sections) formed by wild-type or IL-6 knockout TE11 cells. 
Organoid size is quantified as relative cross-section area, organoid shape quantified as 
deviation from elliptical shape (n=4/clone). (C) Growth kinetics of subcutaneous 
xenograft tumors formed by wild-type or IL-6 knockout TE11 cells (n=6/clone; *p≤0.01). 
P-values calculated via Student’s t-test, p≤0.05 considered statistically significant. 
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Figure 6 
 
Figure 2-6: Targeting IL-6 is a promising novel approach for ESCC therapy. (A) 
Growth kinetics of subcutaneous ESCC xenograft tumors (TE11+FEF3303) treated with 
Tocilizumab or isotype control (i.c.) antibody (n=10/cohort, results from one 
representative study out of three shown; *p=0.009, 0.004, 0.0002). (B) Representative 
images of tumor sections from (A) stained for pSTAT3 and pERK. (C) Quantification of 
staining from (B). P-values calculated via Student’s t-test, p≤0.05 considered statistically 
significant. 
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Figure 7 
 
 
 
56 
 
Figure 2-7: Tumor cell-derived RANTES promotes tumorigenic properties in ESCC. 
(A) Representative images of 3D organotypic cultures (Hematoxylin-Eosin stained 
paraffin-embedded sections) formed by wild-type or RANTES knockout TE11 cells 
(n=2/clone). (B) Representative images of 3D ESCC organoids (brightfield and 
Hematoxylin-Eosin staining of paraffin-embedded sections) formed by wild-type or 
RANTES knockout TE11 cells. Organoid size is quantified as relative cross-section area, 
organoid shape quantified as deviation from elliptical shape (n=4/clone). (C) Growth 
kinetics of subcutaneous xenograft tumors formed by wild-type or RANTES knockout 
TE11 cells (n=6/clone; *p≤0.05). P-values calculated via Student’s t-test, p≤0.05 
considered statistically significant. 
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Figure 8 
Figure 2-8: Targeting RANTES is a promising novel approach for ESCC therapy. 
(A) Growth kinetics of subcutaneous ESCC xenograft tumors (TE11+FEF3303) treated 
with maraviroc or DMSO (n=4/cohort; *p=0.02). (B) Representative images of tumor 
sections from (A) stained for pERK1/2 and pSTAT3. (C) Quantification of staining from 
(B). P-values calculated via Student’s t-test, p≤0.05 considered statistically significant. 
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Figure 9 
 
 
Figure 2-9: Co-inhibition of IL-6 and RANTES signaling may be superior to mono-
therapy. (A) Representative images of 3D organotypic ESCC cultures treated with 
tocilizumab, maraviroc or a combination of both (Hematoxylin-Eosin staining; 
n=2/condition). (B) Quantification of images from (A). P-values calculated via Student’s t-
test, p≤0.05 considered statistically significant. 
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Figure 10 
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Figure 2-10: STAT3 and ERK1/2 signaling mediate ESCC tumorigenesis in vitro. 
(A) Representative images of 3D organotypic ESCC cultures (Hematoxylin-Eosin, 
cleaved caspase 3 and Ki-67 staining; arrows indicate cleaved caspase 3-positive cells; 
n=4/condition). (B) Quantification of images from (A). P-values calculated via Student’s t-
test, p≤0.05 considered statistically significant. 
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Figure 11 
 
Figure 2-11: Potential of targeting IL-6 in multiple types of cancer. (A) Kaplan-Meier 
survival analysis based on differential expression of IL-6 and IL-6R in esophageal cancer 
and pan-cancer (RNAseq data, TCGA; p=0.0065 (esophageal), 3x10-11 (pan-cancer)). 
(B) Representative images of normal oral mucosa and head and neck cancer stained for 
IL-6 by immunohistochemistry, with quantification. (C)  Representative images of normal 
gastric mucosa gastric adenocarcinoma stained for IL-6 by immunohistochemistry, with 
quantification. P-values calculated via Student’s t-test, p≤0.05 considered statistically 
significant. (Data used with permission from Eric Lin). 
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Tables and table legends 
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Table 1 
Cancer Sponsor Treatment modality Phase Identifier 
Tocilizumab (IL-6Rα antibody) 
Ovarian Leiden University 
Medical Center 
Combination (Carbo/Caelyx or 
Carbo/Doxorubicin)  
I/II NCT01637532 
Unresectable 
pancreatic 
carcinoma 
Herlev Hospital Combination (gemcitabine/nab-
paclitaxel) 
II NCT02767557 
Chronic 
lymphocytic 
leukemia 
Hoffmann-La Roche Combination (standard 
premedication, obinutuzumab + 
chlorambucil 
I NCT02336048 
Maraviroc (CCR5 antagonist)   
Metastatic 
colorectal 
cancer 
National Center 
for Tumor Diseases, 
Heidelberg 
Single agent I NCT01736813 
Mogamulizumab/ KW-0761 (CCR4 antibody) 
Adult T-Cell 
Leukemia and 
Lymphoma,  
adult 
Peripheral    
T-Cell 
Lymphoma  
Kyowa Hakko Kirin 
Company, Limited 
Single agent I  
Peripheral    
T-Cell 
Lymphoma 
Kyowa Hakko Kirin 
Pharma, Inc. 
Single agent I/II NCT00888927 
Peripheral    
T-Cell 
Lymphoma 
Kyowa Hakko Kirin 
Pharma, Inc. 
Single agent II NCT01611142 
Peripheral 
T/NK-cell 
Lymphoma 
Kyowa Hakko Kirin 
Company, Limited 
Single agent II NCT01192984 
Cutaneous   
T-Cell 
Lymphoma 
Kyowa Hakko Kirin 
Pharma, Inc. 
Single agent, compared to vorinostat III NCT01728805 
Adult T-cell 
Leukemia-
lymphoma 
Kyowa Hakko Kirin 
Company, Limited 
Single agent II NCT00920790 
Adult T-cell 
Leukemia-
lymphoma 
Kyowa Hakko Kirin 
Pharma, Inc. 
Single agent, compared to  
investigator's choice (pralatrexate; 
gemcitabine/oxaliplatin; 
dexamethasone/cisplatin/cytarabine) 
 
II NCT01626664 
Adult T-cell 
Leukemia-
lymphoma 
Kyowa Hakko Kirin 
Company, Limited 
Single agent, compared to  
VCAP/AMP/VECP(mLSG15) 
II NCT01173887 
 
Table 2-1: Clinical trials targeting IL-6 or RANTES signaling in cancer. 
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Chapter 3 CHAPTER 3: Cytokine regulation of the immunosuppressive 
microenvironment in ESCC 
 
The data in chapter 3 have been published in Cancer Research. 
Karakasheva T., Waldron T. et al., 2015. Cancer Research Oct 1; 75(19):4074-85 
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Abstract 
Myeloid derived suppressor cells (MDSCs) are an immunosuppressive 
population of immature myeloid cells found in advanced stage cancer patients and 
mouse tumor models.  Production of inducible nitric oxide synthase (iNOS) and 
arginase, as well as other suppressive mechanisms, allow MDSCs to suppress T cell-
mediated tumor clearance and foster tumor progression, in addition to other 
mechanisms such as fostering angiogenesis and inducing activation of fibroblasts. We 
have identified CD38 as playing a vital role in MDSCs biology in a murine model of 
ESCC.  CD38 belongs to the ADP-ribosyl cyclase family and possesses both 
ectoenzyme and receptor functions.  It has been described to function in early myeloid 
cell differentiation, cell activation and neutrophil chemotaxis.  We found that CD38 
expression in MDSCs is evident in several mouse tumor models, and CD38high MDSCs 
are more immature than CD38low or CD38neg MDSCs, suggesting a potential role for 
CD38 in the maturation halt found in MDSC populations.  CD38high MDSCs also possess 
a greater capacity to suppress activated T cells, and promote tumor growth to a greater 
degree than CD38low MDSCs, likely as a result of increased iNOS production. Tumor-
derived factors, including IL-6, IGFBP-3 and CXCL16 (identified by us), play a role in the 
induction of CD38 expression.  This work may have implications for use of  FDA-
approved anti-CD38 therapy in patients with solid tumors where MDSCs are 
upregulated. 
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Introduction 
The immune system (both innate and adaptive) plays an essential role in limiting 
tumor growth; therefore, tumor progression requires escape from immune surveillance. 
One of the mechanisms that allows for tumor escape is the activation and expansion of 
immunosuppressive cell populations, including but not limited to, regulatory T cells 
(Tregs) and myeloid derived suppressor cells (MDSCs) (Schreiber et al., 2011), the latter 
also referred to as immature myeloid cells. Certain therapeutics have been 
demonstrated to have potential efficacy against MDSCs (Waldron, T J, Quatromoni G J, 
Karakasheva, T A, Singhal, S, Rustgi, 2013); however, the need for more selective anti-
MDSC therapeutics remains. 
 MDSCs have been observed in a number of mouse tumor models and represent 
a heterogeneous population of immature monocytes, macrophages, granulocytes, and 
dendritic cells that are identified by their CD11b+Gr-1+ phenotype in mice. The first 
human MDSC population was identified in head and neck cancer (Pak et al., 1995), and 
has since been since documented in cancers of the esophagus (Gabitass et al., 2011), 
stomach (Gabitass et al., 2011), pancreas (Gabitass et al., 2011; Schmielau and Finn, 
2001), lung (Liu et al., 2010), kidney (Zea et al., 2005), colon (Schmielau and Finn, 
2001), skin (melanoma) (Filipazzi et al., 2007), prostate (Vuk-Pavlović et al., 2010), and 
breast (Schmielau and Finn, 2001). The immunophenotype of human MDSCs varies 
(Greten et al., 2011), however, their immunosuppressive mechanisms match those 
found in murine CD11b+Gr-1+ MDSC populations.   
MDSCs induce immune suppression primarily through the inhibition of T cell-
mediated tumor clearance (Gabrilovich and Nagaraj, 2009), but can also promote 
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inhibition of NK cells (Li et al., 2009) and activation of Tregs (Huang et al., 2006; Serafini 
et al., 2008).  Arginase-1 (ARG1) and inducible nitric oxide synthase-2 (iNOS) provide 
the bulk of the enzymatic activity required for MDSCs to suppress proliferation and 
activation of T cells (Gabrilovich and Nagaraj, 2009). ARG1 deprives T cells of arginine 
by converting L-arginine into urea and L-ornithine, thereby leading to reduced 
expression of CD3ζ chain, which renders T cells unable to respond to activation signals 
(Rodriguez et al., 2003, 2004).  iNOS inhibits T cell function by a variety of mechanisms, 
including the inhibition of JAK3/STAT5 signaling (Bingisser et al., 1998), MHC Class II 
expression (Harari and Liao, 2004) and induction of apoptosis (Rivoltini et al., 2002).   
 CD38 expression is a common characteristic to several immunosuppressive cell 
types.  Foxp3+CD25+CD4+ Tregs expressing high levels of CD38 possess greater 
immunosuppressive activity than CD38low Tregs (Patton et al., 2011). CD38+CD8+ T cells 
suppress proliferation of CD4+ effector T cells, which requires secretion of IFNγ and cell-
to-cell contact (Bahri et al., 2012).  Similarly, CD19+CD24hiCD38hi B cells inhibit the 
differentiation of T helper 1 cells through an IL-10-dependent mechanism, and their 
dysfunction may play a role in autoimmune disorders such as systemic lupus 
erythematosus (Blair et al., 2010).  
CD38 is a member of the ribosyl cyclase family and is expressed on the surface 
of diverse immune cells, including B cells, T cells, NK cells and myeloid cells (Malavasi 
et al., 2008a).  CD38 possesses independent ectoenzyme and receptor functions.  As an 
ectozyme, CD38 catalyzes the synthesis and hydrolysis of cyclic ADP-ribose (cADPR), 
converting NAD+ to ADP-ribose (ADPR), as well as cADPR into ADPR (Lee, 2012; 
Malavasi et al., 2008a). Furthermore, at acidic pH, CD38 catalyzes the synthesis and 
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hydrolysis of nicotinic acid adenine dinucleotide phosphate (NAADP) (Lee, 2012; 
Malavasi et al., 2008a). Both reactions are important for calcium signaling, specifically 
for mobilization of intracellular Ca2+ (Lee, 2012). Receptor activity of CD38 has been 
documented in several immune cell types, where it is dependent on localization to the 
lipid rafts and association with professional signaling complexes (Malavasi et al., 2008a). 
In both mouse and human myeloid cells, ligation of CD38 leads to suppressed growth 
and survival leading to loss of the most differentiated immune populations (Todisco et 
al., 2000). 
We have identified CD38 as a novel marker for MDSCs that possesses greater 
immunosuppressive capacity, thereby promoting tumor growth in vivo. Mechanistically, 
CD38 promotes expansion of the monocytic MDSC population and regulates expression 
of the effector molecule iNOS by these cells. Importantly, we have established for the 
first time that several cytokines, specifically IFNg, TNFa, IGFBP-3, CXCL16, and IL-6, 
are capable of inducing CD38 expression in MDSCs. Finally, we have demonstrated that 
administration of an anti-CD38 monoclonal antibody slows disease progression in tumor-
bearing mice.  
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Results 
CD38high MDSCs possess greater immunosuppressive and tumor-promoting 
capacity than CD38low MDSCs 
We have previously demonstrated that MDSCs play a fundamental role in tumor 
initiation and progression in a spontaneous genetic mouse model of ESCC (L2-
Cre;p120f/f) (Stairs et al., 2011), and our next goal was to identify genes associated with 
an immature myeloid phenotype that contribute to the tumor promoting activities of 
MDSCs. To that end, we performed microarray analysis of splenic MDSCs from tumor-
bearing L2-Cre;p120f/f mice and age-matched littermate controls  and identified Cd38 
(ranked fifth highest among all genes tested as a candidate gene of interest), as it has 
roles in both innate and adaptive immunity in mice and humans, including, but not limited 
to chemotaxis of murine and human neutrophils, early myeloid differentiation and 
lymphoid cell activation (Karakasheva et al., 2015).  
These findings led us to the hypothesis that CD38high MDSCs possess greater 
immunosuppressive potential than CD38low MDSCs.  To test our hypothesis, we FACS-
sorted both CD38high and CD38low populations from mice bearing ESCC tumors 
generated by flank injections of the HNM007 cell line in syngeneic C57BL/6 recipients 
and tested their capacity to suppress OT-1 T cell growth following stimulation with 
cognate antigen.  The capacity of total CD11b+Gr-1+, CD11b+Gr-1+CD38low, and 
CD11b+Gr-1+CD38high cells to suppress T cell proliferation after stimulation was tested.  
CD38high MDSCs demonstrated significantly greater T cell suppressive capacity, 
compared to their CD38low counterparts (Fig. 1A), at 2:1 OT-1 to MDSC ratio, while a 
trend of increased suppression was observed at 1:1 and 4:1 ratios. 
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Next, we evaluated the impact of coinjection of CD38high MDSCs with HNM007 
cells on tumor growth. Tumor volumes in the CD38High group were significantly larger 
than the CD38Low tumors when measured on days 6 and 10 (Fig. 1B), and larger than 
control HNM007 tumors at days 8, 10 and 13 (Fig. 1B). No differences in size were 
detected between the CD38Low and control HNM007 tumors. These results suggest that 
CD38high MDSCs possess greater tumor-promoting capacity than CD38low MDSCs in 
vivo. 
 We next investigated whether CD38 is required for immunosuppressive function 
of MDSCs. We therefore tested the capacity of Cd38-/- and Cd38+/+ (wt) CD11b+Gr-1+ 
cells sorted from mice bearing HNM007 tumors to suppress growth of OT-1 T cells 
following antigen stimulation and found that Cd38-/- CD11b+Gr-1+ cells exhibited 
significantly reduced immunosuppressive capacity at 1:1 and 4:1 OT-1 to MDSC ratio 
(Fig. 1C).  
IFNγ, TNFα, CXCL16, IGFBP-3 and IL-6 induce the expression of CD38  
 We have observed that unlike the HNM007 ESCC cell line, the tumors generated 
by flank injection of the AKR ESCC line do not induce high expression of CD38 on the 
surface of MDSCs (Fig. 2). This prompted us to employ these two cell lines to better 
understand the tumor cell-specific signaling pathways that result in increased expression 
of CD38.  We performed ex vivo differentiation of bone marrow using GM-CSF, IL-4 (the 
cytokines required for generation of CD11b+Gr-1+ cells from bone marrow progenitors 
(Youn et al., 2008)) and either HNM007 or AKR conditioned media.   HNM007 
conditioned medium induced cells to express CD38 while AKR conditioned medium did 
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not (Fig. 3B). Since IFNγ and TNFα are key components of the pro-inflammatory milieu 
and both are known activators of CD38 transcription (Malavasi et al., 2008a), we 
performed an ex vivo differentiation assay with the addition of IFNγ, TNFα, or both and 
found that both factors induced CD38 expression in the CD11b+Gr-1+ population, while 
the combination of IFNγ and TNFα induced the most profound effect (Fig. 3B).  We 
subsequently performed a cytokine array using media collected from the ex vivo 
differentiation experiments and compared the levels of 62 cytokines present in the 
culture medium derived from HNM007 conditioned medium to culture medium derived 
from AKR conditioned medium.  Several factors including CXCL16, IGFBP-3 and 
RANTES were present at higher levels in the HNM007 conditioned medium samples 
after 24 hours in culture (Table 1). CXCL16 and IGFBP-3 levels were maintained at 
higher levels in HNM007 conditioned media-containing cultures after 120 hours (Table 
1), suggesting that either of these two factors, or both, may play a role in induction of 
CD38.  In addition, the pro-inflammatory cytokine IL-6, a predicted activator of CD38 
transcription (Malavasi et al., 2008b), was elevated in HNM007 conditioned media-
containing cultures after 24 and 120 hours, albeit not as dramatically as CXCL16 or 
IGFBP-3 (Table 1).  We tested next the capacity of recombinant IL-6, CXCL16 and 
IGFBP3 alone or in combination to increase CD38 expression in our ex vivo 
differentiation experiments.  Addition of the combination of IL-6, CXCL16 and IGFBP3 
was able to induce CD38 expression in MDSC cultured with AKR conditioned medium 
(Fig. 4B). Nevertheless, the most potent induction of CD38 expression was observed 
when IFNγ and TNFα were added to the culture. The importance of IL-6 in ESCC 
pathogenesis is elucidated in Chapter 2 of this thesis.  
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Cross-linking of CD38 by an agonistic antibody impairs expansion and survival of 
CD11b+Gr1+ cells in vitro and suppresses tumor growth in vivo 
 In order to test whether cross-linking of CD38 with a monoclonal antibody has an 
effect on MDSC function(s), we performed a colony-formation assay. CD11b+Gr-1+ cells 
were isolated from the spleens of diseased L2-cre;p120-/- mice and cultured in 
methylcellulose-based medium in the presence of an anti-CD38 monoclonal antibody 
(NIM-R5) or an isotype control.  Addition of an anti-CD38 antibody inhibited the growth of 
colonies from sorted splenic CD11b+Gr-1+ cells (Fig. 5A and 5B). The effect of the anti-
CD38 antibody remained the same regardless of whether splenocytes were pre-sorted 
(Fig. 5A and 5B).  These data demonstrate that anti-CD38 treatment inhibits MDSC 
proliferation and survival in vitro independent of stromal support.  We similarly tested the 
effect of anti-CD38 treatment in suspension culture.  FACS-sorted CD11b+Gr-1+ cells 
survive only a few days in culture, but their survival is significantly reduced in the 
presence of anti-CD38 antibody (Fig. 5C).  We have also tested whether cross-linking of 
CD38 inhibits the accumulation of CD11b+Gr-1+CD38high cells produced by our ex vivo 
culture of bone marrow in the presence of tumor cell conditioned medium, IL-4 and GM-
CSF. Using a CD38 antibody (clone 90) different from NIM-R5, we observed a dose-
dependent decrease in the CD38 expression within the CD11b+Gr-1+ population (Fig. 
5D).  Given that the proportion of CD11b+Gr-1+ cells within the bone marrow culture 
remained consistent (25-30%; data not shown) the CD38 expression data demonstrate 
that the CD11b+Gr-1+CD38high population is reduced as a result of CD38 cross-linking. 
Lastly, we have attempted a pilot study investigating the effect of CD38 antibody 
treatment on tumor growth rate in vivo in a subcutaneous transplant model of ESCC. 
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HNM007 tumor-bearing mice were treated every 48 hours with anti-CD38 (NIM-R5) or 
isotype control (IgG2a) antibody, starting on day 5 post-injection. We have observed a 
significant decrease in tumor volume in the NIM-R5-treated cohort, compared to the 
IgG2a-treated cohort (Fig. 5E). These data demonstrate the importance of CD38 for 
MDSC-mediated tumor progression, as well as suggest targeting CD38 as an 
experimental approach to ESCC therapy. 
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Discussion 
We have identified CD38 as a functional marker of MDSCs with higher 
immunosuppressive capacity. Yet, we did not know what factors are responsible for 
induction of CD38 expression in this population. Interestingly, two different ESCC cell 
lines used in our studies exhibited differential capacities to induce expansion of a 
CD11b+Gr-1+CD38high MDSC population, thereby suggesting that the tumor cells are 
responsible for initiating the signaling cascade that results in the increased CD38 
expression on MDSCs.  Based upon our ex vivo studies, the tumor-derived signals may 
act directly on immature myeloid cell populations present in hematopoietic tissues to 
promote CD38 expression.   
Several factors are likely to be responsible for activating CD38 expression, 
including IFNγ, TNFα, IL-6, IGFBP-3 and CXCL16.  Transcriptional regulation of CD38 
expression by both IFNγ and TNFα has been reported (Malavasi et al., 2008a), and we 
demonstrated that both are capable of inducing cultured bone marrow derived 
CD11b+Gr-1+ cells to express CD38.  As both IFNγ and TNFα are often produced during 
chronic inflammation, they may be primary inducers of CD38 expression and the 
resulting changes in immature myeloid cell populations (Fig. 6).  In fact, use of a TNFα 
inhibitor (etanercept) has been demonstrated to inhibit suppressive capacity of MDSCs 
and induce differentiation in a murine model of chronic inflammation (Sade-Feldman et 
al., 2013). Coupled with our observation that TNFα potently induces CD38 expression, 
the finding that MDSCs from both Cd38-/- and Tnf-/- mice exhibit reduced iNOS levels 
(Levy et al., 2012; Mayo et al., 2008) suggests that TNFα likely activates CD38 
expression in MDSCs, thereby leading to the induction of iNOS expression in vivo.  
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IL-6 is a major regulator of activation of STAT3 and a key transcriptional factor 
for establishment of immunosuppressive microenvironment within the tumor (Kortylewski 
et al., 2005).  Importantly, a recent report demonstrated correlation between increased 
serum levels of IL-6 and poor prognosis, as well as with the expansion of MDSC-like 
population (CD11b+CD14+HLA-DR-) in peripheral blood of ESCC patients (Chen et al., 
2014). It has been shown that overabundance of activated STAT3 stalls differentiation of 
myeloid cells, resulting in expansion of the immature myeloid cell pool (Nefedova et al., 
2004). In MDSCs, STAT3 activation enhances production of the S100A8/A9 pro-
inflammatory factors, which also contribute to maintenance of a reduced differentiation 
state (Cheng et al., 2008; Sinha et al., 2008). These data are in agreement with our 
observation that IL-6 can promote CD38 expression on MDSCs generated ex vivo, since 
CD38high MDSCs are less differentiated than their CD38low counterpart (Karakasheva et 
al., 2015).  At the same time, in lymph nodes, B cell-derived IL-6 prompts resident 
macrophages to secrete CXCL10, which promotes differentiation of B cells into 
CD138+CD38+ plasma cells (Xu et al., 2012). This report supports our observation that 
IL-6 can induce CD38 expression; it also implies that in our ex vivo differentiation system 
this process may also be mediated by bone marrow-derived macrophages.   
Our finding of a CXCL16-mediated response in MDSC has not been described 
previously. However, it is interesting to note that CXCL16 is induced by IFNγ and TNFα 
(Abel et al., 2004).  Dendritic cells express CXCL16, which in turn is found in T cell 
replete areas of the spleen and lymph nodes (Matloubian et al., 2000). CXCL16 binds its 
cognate receptor, CXCR6, and induces the migration of T and NK cell populations 
(Matloubian et al., 2000). Thus, CXCL16 is found in tissues where MDSCs and T cells 
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may interact and may serve to recruit T cells to these regions.  If CXCL16 can also 
induce MDSCs to adopt a more immunosuppressive phenotype, as we suggest, it could 
greatly contribute to T cell suppression. 
IGFBP-3 is most widely known as the main binding partner for the insulin-like 
growth factors (IGFs), and as a part of this complex IGFBP-3 can stimulate cell 
proliferation, differentiation, cell survival and enhanced metabolic activity. However, the 
same signaling complex can suppress proliferation and induce apoptosis. Furthermore, 
IGFBP-3 can act independently of IGF either by entering the nucleus and directly binding 
DNA or by binding to several receptors on the cell surface, for example TGFβRV (Jogie-
Brahim et al., 2009).  The potential effects of IGFBP-3 on hematopoietic cells have not 
been investigated, however, there are several reports addressing its role in cancer. For 
example, IGFBP-3-induced increase in intracellular Ca2+ levels has been reported in 
breast cancer and myoblast cell lines (Seurin et al., 2013). This area certainly requires 
additional investigation, but it is plausible to hypothesize that since Ca2+ signaling is 
important for multiple immunomodulatory processes (Sochorová et al., 2009; Vellenga et 
al., 1993; Vukcevic et al., 2010), IGFBP-3 may potentiate expansion of the more 
immunosuppressive CD38High MDSCs. 
The chemokine RANTES was also associated with conditions promoting CD38 
expression in the ex vivo differentiation culture (Table 1). We have yet to validate these 
results with recombinant RANTES, however, there is published evidence supporting its 
role in immunosuppressive capacity of MDSCs. Interestingly, monocytic MDSCs from 
tumor-bearing Rantes-/- mice were shown to be less immunosuppressive than MDSCs 
from Rantes+/+ mice (Zhang et al., 2013). Furthermore, this phenotype was attributed to 
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reduced production of iNOS by these cells (Zhang et al., 2013). These data seem to 
correlate with our findings of monocytic MDSCs relying on iNOS for their 
immunosuppressive capacity (Karakasheva et al., 2015). 
We also demonstrate here that targeting CD38 with a monoclonal antibody 
resulted in suppressed tumor growth rate in vivo; therefore, anti-CD38 therapy may 
represent a novel approach to targeting this immunosuppressive population in cancer 
treatment strategies. Recently, an anti-CD38  monoclonal antibody (daratumumab)  was 
shown to be efficient in treatment of multiple myeloma (MM) in pre-clinical studies (de 
Weers et al., 2011). Moreover, in early-stage clinical trials daratumumab was found to be 
effective in patients with relapsed MM both as a single agent and in combination 
therapy, which resulted in its approval for MM and designation of the drug as 
“breakthrough therapy” by the US FDA (Laubach et al., 2014). A similar approach may 
allow ablation of MDSCs in patients with advanced stage solid cancer, and thus, may be 
suitable as an adjuvant to conventional therapies.  
The expression pattern of CD38 in a broad range of cell types can raise a 
concern about potential adverse effects of anti-CD38 therapy (discussed in (Stevenson, 
2006)), however, early clinical studies of daratumumab in MM have demonstrated an 
acceptable safety profile, suggesting that an appropriate dosage and treatment schedule 
allow for minimizing of the effects of targeting CD38 in normal tissue (Laubach et al., 
2014). In addition, it is known that daratumumab induces killing of CD38-expressing cells 
through antibody-dependent cell-mediated cytotoxicity (ADCC) (Phipps et al., 2015). The 
main caveat of such a mechanism is that it only works on cells expressing high copy 
numbers of the target antigen, therefore, certain populations may be left unharmed. This 
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emphasizes the need for development of a new generation of CD38-targeting 
therapeutics. One of the options would be to conjugate the antibody to a cytotoxic drug 
that would be cleaved upon the internalization of CD38. Another promising avenue is 
development of bispecific antibodies, which will allow for a more selective targeting of 
immunosuppressive populations. Finally, the efficacy and specificity of CD38 binding-
induced ADCC can be fine-tuned via modifications in the Fc domain of the antibody (Liu 
et al., 2014). 
 Like the robust immunosuppressive characteristics of CD38high MDSCs that we 
describe in this study, CD38high regulatory T cells possess enhanced suppressive 
potential compared to CD38low counterparts (Bahri et al., 2012; Patton et al., 2011). This 
may indicate that the evolution of suppressive immune populations has selected for the 
cells that are capable of expressing CD38.  Furthermore, this suggests that anti-CD38 
therapy may present the advantage of targeting several immunosuppressive cell types at 
the same time.    
 We tested the effects of anti-CD38 monoclonal antibody (mAb) treatment in vitro 
and observed a reduction in survival of CD11b+Gr-1+ cells sorted from the spleens of 
tumor-bearing L2-cre;p120-/-. Furthermore, we demonstrated that ex vivo production of 
CD11b+Gr-1+CD38high cells was inhibited by treatment with anti-CD38 mAb.  While the 
overall production of CD11b+Gr-1+ cells was unaffected, the reduction of CD11b+Gr-
1+CD38high population may provide the benefit of reducing numbers of the most 
immunosuppressive MDSC population.  In addition, our data suggest that the 
CD11b+Gr-1+CD38high population likely possesses survival and self-renewal capacity 
absent in the CD11b+Gr-1+CD38low populations. Anti-CD38 mAb treatment of sorted and 
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unsorted splenocytes led to a loss of all CD11b+Gr-1+ cells, whereas control antibody 
treated cultures were capable of colony formation and exhibited greater survival 
potential.  However, when bone marrow cultures were treated with anti-CD38 mAb, only 
the CD11b+Gr-1+CD38high cells were lost, suggesting that a progenitor population 
present in the bone marrow, but likely absent in the spleen, may be capable of 
replenishing the CD11b+Gr-1+CD38low cell population. 
The efficacy of immunotherapy has been demonstrated in several tumor types 
(Brahmer et al., 2010, 2012; Hodi et al., 2010; Robert et al., 2013; Topalian et al., 2012). 
Several of the most promising approaches function through impairment of T cell 
suppression mediated by antigen-presenting cells, as in the case of anti-CTLA-4 therapy 
(Ipilimumab) (Hodi et al., 2010; Robert et al., 2013), or suppression mediated by tumor 
cells, as in anti-PD-1 therapy (Brahmer et al., 2010; Topalian et al., 2012).  MDSCs 
represent another facet of the T cell suppression repertoire found in cancer that merits 
further investigation as a potential therapeutic target (Marigo et al., 2008).  In this study, 
we have identified CD38 as being suitable for potential MDSC targeting, and useful in 
the identification of potently immunosuppressive MDSC populations. Thus, anti-CD38 
monoclonal antibody therapy (de Weers et al., 2011) may hold potential for targeting 
CD38-expressing MDSCs (Chillemi et al., 2013) in patients with solid tumors.  
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Materials and methods 
Cell lines and reagents  
AKR and HNM007 mouse ESCC tumor lines have been described previously 
(Opitz and Harada, 2002; Takaoka et al., 2004). Cells were maintained in DMEM + 10% 
FBS and passaged or harvested at ~80% confluency. Recombinant mouse CXCL16, 
GM-CSF, IGFBP-3, IL-4, IL-6 were purchased from Peprotech. TNFα was from R&D. 2-
mercaptoethanol was purchased from Sigma. Anti-CD38 monoclonal antibody (clone 
NIM-R5) for in vitro and ex vivo studies was purchased from Abcam. Anti-CD38 
monoclonal antibody (clone NIM-R5) for in vivo studies was a kind gift from Dr. Fabio 
Malavasi. The isotype control antibody (rat IgG2a) was purchased from BioXcell. 
 
Antibody 
Vendor Cat. number 
Murine Gr-1 (PE) BioLegend 108408 
Murine Ly-6C (PerCP) BioLegend 128027 
Murine Ly-6G (FITC) BioLegend 127605 
Murine CD11b (APC) BioLegend 101212 
Murine CD38 (FITC) BioLegend 102705 
Murine CD45 (FITC) BioLegend 103107 
 
Flow cytometry and cell sorting 
Single cell suspensions were prepared from mouse bone marrow or spleen by 
mechanical disruption.  Red blood cells were lysed, and the remaining leukocytes were 
washed with PBS, and resuspended in PBS + 2% FBS. Samples were analyzed on a 
FACScalibur (BD) or LSRII (BD).  Cell sorting for multiple markers was performed on a 
FACSAriaII (BD).  Data were analyzed using FlowJo (Treestar). 
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Generation of MDSCs 
The Institutional Animal Care and Use Committee (IACUC) at the University of 
Pennsylvania approved all animal studies. Mice were housed under a 12-hour light/dark 
cycle and fed ad libitum. Three mouse ESCC models were used for production of 
MDSCs.  The first is the L2-Cre;p120ctnf/f mouse model, which has been described  
previously by us and involves the conditional knockout of p120ctn in the squamous oral 
cavity, esophagus and forestomach, resulting in invasive squamous cell cancer with 
desmoplasia and the specific recruitment of MDSCs (Stairs et al., 2011).  We used also 
two syngeneic transplantation models utilizing the HNM007 and AKR esophageal 
squamous cell carcinoma (ESCC) cell lines. HNM007 or AKR cells were subcutaneously 
injected into C57BL/6J (Jackson Labs) and Cd38-/- mice (gift from Dr. Eduardo Chini). 
Mice were aged until tumors reached a volume of 0.8cm3. Spleens and bone marrow 
were harvested at euthanasia for MDSC isolation.   
Colony formation and cell recovery assays 
200,000 cells were seeded into 35 mm plates containing 1 ml MethoCult medium 
(M3534; Stem Cell Technologies).  Anti-CD38 monoclonal antibody and IgG2a isotype 
control were used at 10ug/mL. Colonies were counted after 7 days. For recovery assays, 
5x105 MDSCs were seeded in complete RPMI 1640 medium supplemented with 
antibodies; cells were quantified by Trypan Blue exclusion using a Countess automated 
cell counter (Invitrogen).   
T cell suppression 
CD11b+Gr-1+, CD11b+Gr-1+CD38low, and CD11b+Gr-1+CD38high cell populations 
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were sorted by flow cytometry.  Antigen-specific CD8+ T cell suppression was tested as 
described previously (Stairs et al., 2011). Splenocytes from OT-1 mice were activated by 
addition of the OVA peptide to culture medium. The cultures were pulsed with 3H-labeled 
thymidine, and 3H incorporation was assessed 24 hours later to quantify cell proliferation 
rates. 
Ex vivo MDSC differentiation  
The generation of MDSCs from bone marrow has been described previously 
(Youn et al., 2008).  Bone marrow cells were isolated from femurs and tibias of 
C57BL/6J mice, and the red blood cells were lysed. The remaining cells were seeded 
into 24-well plates (1x106 per well) in RPMI + 10% FBS supplemented with 0.1 ng/ml 
GM-CSF, 0.1 ng/ml IL-4, 50 uM 2-mercaptoethanol (Sigma), 10 ng/ml TNFα, 10 ng/ml 
IFNγ, 100 ng/ml IL-6 100 ng/ml CXCL16, 100 ng/ml IGFBP-3, and 50% v/v of either 
DMEM + 10% FBS or conditioned medium (CM) from HNM007 or AKR cells.  For 
antibody treatment experiments, anti-CD38 monoclonal antibody and IgG2a isotype 
control antibody were added at 10ug/ml. The cells were cultured at 37°C in 5% CO2 
humidified atmosphere. On day 3 of culture the spent media were replaced with fresh 
media supplemented with cytokines and CM. The cells were harvested on day 5 and 
analyzed by flow cytometry.   
Cytokine Array 
Media from ex vivo differentiation cultures was collected and snap frozen after 1 
or 5 days of culture.  Array analysis was performed using the mouse cytokine array C3 
(Raybiotech) according to the manufacturer’s protocol.  Cytokines tested included Axl, 
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BLC, CD30 Ligand, CD30, CD40, CRG-2, CTACK, CXCL16, Eotaxin-1, Eotaxin-2, Fas 
Ligand, Fractalkine, G-CSF, GM-CSF, IFN-gamma, IGFBP-3, IGFBP-5, IGFBP-6, IL-1 
beta, IL-10, IL-12 p40/p70, IL-12 p70, IL-13, IL-17, IL-1 alpha, IL-2, IL-3, IL-3 Rb, IL-4, 
IL-5, IL-6, IL-9, KC/CXCL1, Leptin/OB, Leptin R, LIX, L-Selectin, Lymphotactin, MCP-1, 
MCP-5, M-CSF, MIG, MIP-1 alpha, MIP-1 gamma, MIP-2, MIP-3 beta, MIP-3 alpha, PF-
4, P-Selectin, RANTES, SCF, SDF-1 alpha, sTNFRI, sTNFRII, TARC, TCA-3, TECK, 
TIMP-1, TNF alpha, Thrombopoietin, VCAM-1, and VEGF-A.  Quantification of results 
was performed using the ImageJ protein array analyzer.  Results were normalized to 
positive controls to allow for comparison of relative expression levels.   
ESCC/MDSC Co-transplantation 
C57BL/6J recipient mice from Jackson Labs were injected subcutaneously with a 
mixture of 2.5x105 syngeneic HNM007 tumor cells with either 2.5x105 CD38low or CD38hi 
MDSCs obtained from HNM007 tumor-bearing C57BL/6J mice. Recipient mice injected 
with 2.5x105 syngeneic HNM007 tumor cells alone served as controls. Measurements 
were taken every 2-3 days once tumors became palpable.   
Statistical analysis 
The Student t-test was used to determine whether there is significant difference 
between two experimental groups (P≤0.05 was considered statistically significant). 
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Figures and figure legends 
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Figure 1 
 
Figure 3-1: CD38high MDSCs are more immunosuppressive and promote tumor 
growth more efficiently than the CD38low MDSCs.  (A) CD38high and CD38low MDSCs 
from tumor-bearing p120-/- mice were used in a T-cell suppression assay (n=3; *, 
P=0.0007). (B) C57BL/6 mice were injected with HNM007 cells in combination with 
MDSCs (CD38high or CD38low) or alone (n= 5 per group). Tumor volumes were compared 
between the CD38high and CD38low groups (*, P=0.004 and 0.03), and between CD38high 
and control HNM007 tumors (**, P= 0.01, 0.003, and 0.01). (C) Splenic MDSCs from 
HNM007 tumor-bearing Cd38-/- or wt mice were used in a T-cell suppression assay (*, 
P=0.003 and 0.04). P-values calculated via Student’s t-test, p≤0.05 considered 
statistically significant. 
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Figure 2 
 
 
Figure 3-2: HNM007, but not AKR ESCC cell line promotes expansion of CD38high 
MDSCs.  Splenocytes from AKR or HNM007 syngeneic subcutaneous transplant tumor-
bearing mice were analyzed by flow cytometry. CD38 expression levels on the 
CD11b+Gr-1+ subpopulation are shown as histograms. 
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Figure 3 
 
 
Figure 3-3: HNM007 conditioned medium, IFNγ and TNFα induce CD38 expression 
in an ex vivo differentiation model. (A) Scheme of the ex vivo differentiation assay: 
bone marrow (BM) extracted from naïve C57BL/6 mice is cultured for 120 hours in the 
presence of conditioned media (CM) from either AKR or HNM007 cell lines, 
supplemented with a cocktail of cytokines. (B) CD38 expression in CD11b+Gr-1+ cells 
from ex vivo differentiation cultures was tested by FACS (MFI = mean fluorescence 
intensity; n=3; *P=10-4; **P=6x10-4; ***P=2.5x10-5). P-values calculated via Student’s t-
test, p≤0.05 considered statistically significant. 
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Figure 4 
 
 
Figure 3-4: IL-6, IGFBP3 and CXCL16 are novel regulators of CD38 expression in 
an ex vivo differentiation model. (A) Scheme of the ex vivo differentiation model 
assay, followed by a cytokine array. (B) CD38 expression in CD11b+Gr-1+ cells from ex 
vivo differentiation cultures was tested by FACS (MFI = mean fluorescence intensity; 
n=3; *P=0.05; **P=0.005). P-values calculated via Student’s t-test, p≤0.05 considered 
statistically significant. 
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Figure 5 
 
 
90 
 
Figure 3-5:  Anti-CD38 monoclonal antibody inhibits Gr-1+CD11b+ expansion and 
survival.  (A) Colony formation of sorted Gr-1+CD11b+ from 6-8 month old p120-/- mice 
grown in methylcellulose-based medium containing cytokines for the detection of 
granulocyte-macrophage progenitors (CFU-GM, CFU-G, CFU-M).  Colonies were 
counted following treatment with anti-CD38 monoclonal antibody (NIMR-5) or isotype 
(IgG2a) control (10ug/ml) for 7 days. Results are representative of two different 
experiments performed in triplicate. (* p=4x10-5) (B) Colonies observed after 7 days of 
culture with anti-CD38 or isotype control.  (C) Cell recovery of sorted Gr-1+CD11b+ from 
p120-/- mice.  Gr-1+CD11b+ cells were isolated, cultured in RPMI with anti-CD38 or 
isotype control antibody, and quantified at indicated time points. (* p=0.0005, **p=5x10-7) 
(D) Ex vivo differentiation of wt bone marrow in the presence of anti-CD38 or isotype 
control antibody.  Cells were cultured for 5 days, and CD38 expression (detected using 
anti-CD38 clone 90) on the surface of CD45+7-AAD-Gr-1+CD11b+ was measured by flow 
cytometry (MFI = mean fluorescence intensity; * p=0.005, ** p=0.0005).  Each treatment 
was performed in triplicate. P-values calculated via Student’s t-test, p≤0.05 considered 
statistically significant.  
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Figure 6 
 
 
Figure 3-6: Model. In mice, tumor progression leads to MDSC expansion. Tumor 
progression leads to amplified signals (such as cytokines) reaching MDSCs, which 
induces a differentiation halt and expansion of CD38high MDSCs with enhanced 
immunosuppressive capacity [mediated by iNOS, which produces nitric oxide (NO)].   
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Tables and table legends 
 
  
93 
 
Table 1 
 
Table 3-1: Cytokines differentially 
secreted in ex vivo bone marrow 
differentiation cultures associated with 
high CD38 expression. Cytokine array 
was performed with media from ex vivo 
differentiation cultures (24 or 120 hours). 
Each cytokine tested in duplicate. 
Difference in normalized expression 
between HNM007 and AKR groups is 
shown.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Cytokine 
Fold-change (HNM007/AKR) 
24h 120h 
 Axl 5.44 - 
BLC 3.83 - 
CTACK 2.77 - 
CXCL16 33.4 7.36 
Eotaxin 4.83 - 
G-CSF 4.39 - 
GM-CSF - 8.96 
IGFBP-3 9.98 14.04 
IGFBP-6 0.08 0.09 
IL-3Rb 2.25 - 
IL-6 2.11 2.20 
KC - 3.14 
LIX 3.52 3.25 
MCP-5 0.38 0.41 
MIG 0.47 - 
MIP-3b 0.11 - 
P-selectin - 4.82 
RANTES 8.97 2.05 
sTNF RII 0.34 - 
VCAM-1 0.37 - 
VEGF - 3.18 
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Chapter 4 CHAPTER 4: Thesis summary and discussion 
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The focus of this thesis was on the mechanisms of dynamic interaction between 
the tumor cells and certain components of the tumor microenvironment (CAFs, immune 
cells) in esophageal cancer. This was prompted by previous research performed by the 
Rustgi lab members, as well as other publications.  
The tumor cell – CAF cross-talk 
Our lab has a long-standing interest in the role of stroma, particularly CAFs, in 
esophageal carcinogenesis. For example, our lab reported a pro-invasive induction of 
cathepsin B in ESCC cells, which was induced by a fibroblast-secreted factor (Andl et 
al., 2010). Another report from our lab elucidated the mechanism where fibroblast-
derived HGF promotes invasion of ESCC cells into the ECM via activation of Met 
receptor signaling within the ESCC cells (Grugan et al., 2010). Furthermore, research 
from our lab identified the matricellular protein periostin as a stroma-derived factor 
essential for invasion of ESCC cells into the ECM (Michaylira et al., 2010). Finally, a 
recent report from our lab has focused on the function of another matricellular protein – 
SPARC – in stromal expansion and metastasis in a murine model of pancreatic cancer 
(Heeg et al., 2016). Not surprisingly, when we investigated the impact of co-culture with 
CAFs on gene expression in ESCC cells, we found the genes encoding periostin, 
SPARC and HGF to be strongly upregulated in response to interaction with fibroblasts 
(Chapter 2, Figure 1a). 
As described in detail in Chapter 2, we chose to study the dynamic interaction 
between CAFs and tumor cells in the esophageal cancer microenvironment, focusing on 
IL-6 and RANTES, the cytokines that mediate (at least partially) this interaction. While in 
this thesis we focus mainly on the role of tumor cell-derived cytokines, it is essential to 
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keep in mind that, in addition to the mechanisms described herein (regulation of tumor 
cell invasion, proliferation and apoptosis), IL-6 and RANTES are likely to be promoting 
tumorigenesis in many other ways. Such mechanisms can include resistance to chemo- 
and radiotherapy, expansion of reactive stroma, lympho- and angiogenesis, induction 
and maintenance of chronic inflammation, as well as formation of an 
immunosuppressive microenvironment (addressed, in part, in Chapter 3). Accompanied 
by their roles in such quality-of-life-affecting conditions as cancer cachexia (Narsale and 
Carson, 2014) and cancer-related pain (Hang et al., 2013), these observations make IL-
6 and RANTES attractive targets for cancer therapy. We provide in this thesis evidence 
of the anti-tumorigenic effects of treatment with tocilizumab or maraviroc in vivo (Chapter 
2, Fig. 6,8) and the superiority of combination treatment, compared to either drug alone, 
in vitro (Chapter 2, Fig. 9). We believe that this approach would bring improved survival 
and quality of life to esophageal cancer patients..  
Cross-talk between MDSCs and tumor cells or CAFs 
The interest in myeloid-derived suppressor cells and their role in ESCC was 
sparked by the fairly unexpected results of investigating the changes in immune cell 
populations in response to tumor progression in the L2-cre;p120f/f mouse model of 
ESCC (Stairs et al., 2011). One of the most pronounced features of tumor-bearing L2-
cre;p120f/f mice was splenomegaly, and upon immunophenotyping of these splenocytes, 
the only population that significantly expanded in response to tumor progression were 
the CD11b+Gr-1+ MDSCs. We set out to determine the genes that could be 
mechanistically linked to alternative differentiation of normal immature myeloid cells into 
MDSCs in tumor-bearing animals, and identified Cd38, a gene encoding a cell surface-
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expressed ectoenzyme receptor (Karakasheva et al., 2015). As described in detail in 
Chapter 3, we proceeded to identify a panel of cytokines, specifically IFNᵧ, TNFα, IL-6, 
CXCL16, IGFBP-3 and RANTES, that are responsible for the induction of CD38 
expression by MDSCs in ESCC. Importantly, these cytokines can be produced by 
multiple components of the TME. For example, IL-6 and RANTES, which are a major 
focus of this thesis, are known to be secreted by the tumor cells, CAFs, immune cells, as 
well as endothelial cells and adipocytes. CXCL16 can also be produced by CAFs 
(Allaoui et al., 2016) and dendritic cells (Matloubian et al., 2000), while IGFBP-3 can be 
produced in the liver, kidney and smooth muscle (Ranke, 2015). These facts suggest the 
existence of intricate signaling networks that regulate the processes contributing to the 
maintenance of immunosuppressive microenvironment, including the expansion of 
CD38+ MDSC population. 
Future perspectives 
The findings presented in this thesis demonstrate the potential of disrupting the 
interaction between tumor cells and stromal components (CAFs, MDSCs) for cancer 
therapy. Furthermore, in many cases this can be achieved by repurposing of drugs 
already in the clinic: tocilizumab, maraviroc and daratumomab have already been 
extensively tested and approved by the FDA, which should dramatically simplify the 
translation of our findings from the bench to the bedside. 
Although the therapeutic approaches investigated herein resulted in significant 
decreases in tumor growth rates, neither was capable of completely eliminating the 
tumor. Therefore, future breakthroughs in cancer therapy will likely depend on 
improvements in drug design and combination therapies. In addition to the combination 
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of tocilizumab and maraviroc proposed in Chapter 2, it is reasonable to expect that 
addition of conventional chemo- or radiotherapy to this treatment scheme could provide 
improved outcomes. At the moment, a new generation of IL-6Rα targeting antibodies is 
being rationally developed in such a way so as to specifically block IL-6 trans-signaling, 
which is considered to be more relevant to carcinogenesis (Hunter and Jones, 2015). In 
contrast to targeting the receptors, it could be beneficial to target downstream 
components of the signaling pathways these receptors activate, such as combining 
small molecule inhibitors of STAT3 and MEK/ERK as described in Chapter 2. This 
approach can decrease the opportunities of cancer cells to acquire resistance to 
targeted therapies, as well as potential compensation by other cytokines in the TME. 
Finally, CD38-targeted therapy could also benefit from a combination with cytotoxic 
drugs or radiation: these approaches are known to activate CD8+ T cells, which would in 
this case cease being suppressed by MDSCs and proceed to clear tumor cells. 
We are also looking forward to expanding our findings from Chapter 2 onto other 
types of cancer. Based on published research and in silico analyses of gene expression 
profiles from the TCGA database, it is evident that the relevance of both IL-6 and 
RANTES spans beyond esophageal cancer: breast cancer (including the most 
aggressive triple-negative subset), KRAS-mutant lung cancer, and colon cancer are 
taking advantage of signaling induced by these cytokines. Therefore, we plan to test the 
targeted therapies evaluated in this thesis in murine models of non-GI cancers.  
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In regard to the basic science aspect of the research presented herein, many 
things remain to be investigated. For example, while in Chapter 3 we defined a subset of 
MDSCs (CD38high monocytic MDSC) that is more immunosuppressive than the total 
MDSC population; this does not diminish the functional impact of granulocytic MDSCs 
on cancer progression. We are working on developing a murine model that would allow 
us to distinguish more accurately between the roles that each MSDC subset plays in 
carcinogenesis. This model utilizes the “suicide gene” methodology by driving 
expression of the herpes simplex virus thymidine kinase under either the Ly-6C or Ly-6G 
promotor. Administration of ganciclovir to these animals will result in specific depletion of 
monocytic or granulocytic MSDCs, respectively. In addition, given the differences 
between murine and human immune systems in general, and the myeloid compartment 
in particular, it would be extremely interesting to investigate the role of CD38 in the 
biology of MDSCs from human cancer patients.  
So far, our research described in Chapter 2 has been focused on the function of 
tumor cell-derived cytokines. Yet, the mechanism through which CAFs in the TME 
induce the tumor cells to secrete those factors (Fig. 1) remains to be elucidated. It is 
likely that multiple factors, both soluble and membrane-bound, regulate this process. 
Identifying these factors would be of utmost importance, since they can also be utilized 
as targets for cancer therapy. 
In conclusion, this thesis provides novel insight into the mechanisms of dynamic 
interaction, or cross-talk, between the tumor cells and two components of the TME 
(CAFs and MDSCs) in esophageal cancer. Interestingly, the findings from both Chapters 
2 and 3 demonstrated the importance of the same two cytokines – IL-6 and RANTES – 
100 
 
in these processes. We have also evaluated a number of novel therapeutic approaches, 
all of which proved to be effective in our murine models of ESCC. We propose that these 
approaches, individually or in combination, might improve existing approaches to cancer 
therapy by disrupting the complex signaling networks in the tumor microenvironment. 
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Figures and figure legends 
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Figure 1 
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Figure 4-1: Model. Chronic inflammation leads to activation of normal fibroblasts and 
their conversion into cancer-associated fibroblasts (CAFs). CAFs acquire a new 
secretory profile, producing pro-tumorigenic cytokines, including IL-6 and RANTES. 
CAFs also interact with the tumor cells directly and alter their gene expression profile, 
enabling tumor cells to secrete high levels of IL-6 and RANTES. These two cytokines 
activate corresponding receptors (IL-6Rα and CCR5) on both tumor cells and CAFs in 
an autocrine-paracrine manner, which results in activation (to a different extent) of the 
STAT3 and ERK signaling pathways. These events result in increased tumor cell 
proliferation, decreased apoptosis, increased invasion and promotes overall tumor 
growth. IL-6 and RANTES also contribute (via induction of CD38 expression) to 
alternative differentiation of normal immature myeloid cells (IMCs) into functional 
myeloid-derived suppressor cells (MDSCs), which establishes an immunosuppressive 
microenvironment within the tumor by suppressing the cytotoxic T cells (CTLs), and 
therefore contributes to increased tumor growth. 
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Chapter 5 APPENDIX: list of abbreviations 
ADPR Adenosine diphosphate ribose 
ARG1 Arginase 1 
Breg Regulatory B cell 
cADPR Cyclic adenosine diphosphate ribose 
CAF Cancer-associated fibroblast 
CCL5 C-C motif chemokine ligand 5 
CCR5 C-C motif chemokine receptor 5 
CRP C-reactive protein 
CTL  Cytotoxic T lymphocyte 
CXCL16 C-X-C motif chemokine ligand 16 
CXCR6 C-X-C motif chemokine receptor 6 
EAC Esophageal adenocarcinoma 
ECM Extracellular matrix 
ESCC Esophageal squamous cell carcinoma 
FACS Fluorescence-activated cell sorting 
GERD Gastroesophageal reflux disease 
GPCR G-protein-coupled receptor 
HGF Hepatocyte growth factor 
HNSCC Head and neck squamous cell carcinoma 
IFN Interferon 
IL-6 Interleukin-6 
IL-6R Interleukin-6 receptor 
iNOS Inducible nitric oxide synthase 
JAK Janus kinase 
mAb monoclonal antibody 
MAPK Mitogen-activated protein kinase 
MCP-1 Monocyte chemoattractant protein-1 
MDSC Myeloid-derived suppressor cell 
MM  Multiple myeloma 
M-MDSC Monocytic myeloid-derived suppressor cell 
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MMP Matrix metalloprotease 
NAD Nocotinamide adenine nucleotide 
PMN-MDSC Perimorphonuclear myeloid-derived suppressor cell 
RANTES Regulated on activation, normal T cell expressed and secreted 
SPARC secreted protein acidic and rich in cysteine 
STAT Signal transducer and activator of transcription 
TAM Tumor-associated macrophage 
TAN Tumor-associated neutrophil 
TME Tumor microenvironment 
TNF Tumor necrosis factor 
Treg Regulatory T cell 
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